

Variability in Individual Responsiveness to Clopidogrel

Journal of the American College of Cardiology

49, 1505-1516

DOI: [10.1016/j.jacc.2006.11.044](https://doi.org/10.1016/j.jacc.2006.11.044)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Prasugrel achieves greater and faster P2Y ₁₂ receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. <i>European Heart Journal</i> , 2007, 29, 21-30.	1.0	408
3	Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel. <i>Journal of Cardiovascular Pharmacology</i> , 2007, 50, 555-562.	0.8	159
4	The Year in Non- σ ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1386-1395.	1.2	3
5	ADP Receptor Antagonism. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 423-432.	1.0	52
6	Clopidogrel- σ Statin Interaction. <i>Journal of the American College of Cardiology</i> , 2007, 50, 296-298.	1.2	50
7	Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1541-1547.	1.2	335
8	ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2007, 98, 838-843.	1.8	203
9	Prasugrel: A Novel Thienopyridine Antiplatelet Agent. A Review of Preclinical and Clinical Studies and the Mechanistic Basis for Its Distinct Antiplatelet Profile. <i>Cardiovascular Drug Reviews</i> , 2007, 25, 357-374.	4.4	227
10	Platelet function, antiplatelet therapy and clinical outcomes: to test or not to test?. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1835-1838.	1.9	13
11	Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1839-1847.	1.9	180
12	The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 54-61.	1.9	200
13	<i>Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention</i> σ Conflicts of interest: Dr. Angiolillo is a consultant and on the speaker's bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami, Florida, and received lecture fees from Bristol Myers Squibb. Dr. Montalescot has been a consultant for and/or received research grants from Sa. <i>American Journal of Cardiology</i> , 2007, 100, 1199-1206.	0.7	110
15	The Antiplatelet Effect of Higher Loading and Maintenance Dose Regimens of Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 612-619.	1.1	52
16	Platelet Hyperaggregability: Impaired Responsiveness to Nitric Oxide (σ Platelet NO Resistance σ) as a Therapeutic Target. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 193-203.	1.3	31
17	Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R). Rationale for the Study and Protocol Design. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 313-320.	1.3	25
20	Antiplatelet therapy in acute coronary syndromes. <i>Current Cardiology Reports</i> , 2008, 10, 327-333.	1.3	5
21	Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?. <i>Clinical Research in Cardiology</i> , 2008, 97, 797-800.	1.5	9
22	Pharmacokinetics of clopidogrel in patients with stent thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1230-1232.	1.9	11

#	ARTICLE	IF	CITATIONS
23	Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1824-1826.	1.9	15
24	Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 2027-2034.	1.9	40
25	Functional Effects of High Clopidogrel Maintenance Dosing in Patients With Inadequate Platelet Inhibition on Standard Dose Treatment. <i>American Journal of Cardiology</i> , 2008, 101, 440-445.	0.7	72
26	Drug-Eluting Stents and Antiplatelet Resistance. <i>American Journal of Cardiology</i> , 2008, 102, 29J-37J.	0.7	5
27	Antithrombotic Therapies in Primary Angioplasty. <i>Drugs</i> , 2008, 68, 2325-2344.	4.9	6
28	The Year in Interventional Cardiology. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2355-2369.	1.2	2
29	Incidence and Clinical Impact of Dual Nonresponsiveness to Aspirin and Clopidogrel in Patients With Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2008, 52, 734-739.	1.2	189
30	Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1968-1977.	1.2	186
31	Elevated Plasma Fibrinogen and Diabetes Mellitus Are Associated With Lower Inhibition of Platelet Reactivity With Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1052-1059.	1.2	118
33	Platelet inhibitor therapy: Current perspectives and emerging novel agents: Introduction. <i>American Heart Journal</i> , 2008, 156, 1S-2S.	1.2	2
34	Current antiplatelet therapies: Benefits and limitations. <i>American Heart Journal</i> , 2008, 156, 3S-9S.	1.2	48
35	Clinical overview of promising nonthienopyridine antiplatelet agents. <i>American Heart Journal</i> , 2008, 156, 23S-28S.	1.2	43
36	Design and rationale of CURRENT-OASIS 7: A randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. <i>American Heart Journal</i> , 2008, 156, 1080-1088.e1.	1.2	140
37	Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. <i>Platelets</i> , 2008, 19, 275-281.	1.1	44
38	Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. <i>European Heart Journal</i> , 2008, 30, 916-922.	1.0	353
39	A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. <i>European Heart Journal</i> , 2008, 29, 2202-2211.	1.0	183
40	Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2008, 30, 426-435.	1.0	192
41	Acute Coronary Syndromes and Diabetes Mellitus. <i>Circulation</i> , 2008, 118, 1607-1608.	1.6	14

#	ARTICLE	IF	CITATIONS
42	Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. <i>European Heart Journal</i> , 2008, 29, 1729-1738.	1.0	32
43	Adjunctive antithrombotic therapy during primary percutaneous coronary intervention. <i>European Heart Journal Supplements</i> , 2008, 10, J2-J14.	0.0	0
44	Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 226-232.	1.4	3
45	New antiplatelet therapies in development. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, S11-S15.	0.5	2
47	Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose. <i>Circulation</i> , 2008, 118, 1225-1233.	1.6	87
48	Prasugrel: a novel platelet ADP P2Y ₁₂ receptor antagonist. A review on its mechanism of action and clinical development. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2893-2900.	0.9	43
49	Clopidogrel Use in Coronary Heart Disease and Percutaneous Coronary Intervention. <i>Journal of Investigative Medicine</i> , 2008, 56, 689-700.	0.7	3
50	Coexisting Polymorphisms of P2Y ₁₂ and CYP2C19 Genes as a Risk Factor for Persistent Platelet Activation With Clopidogrel. <i>Circulation Journal</i> , 2008, 72, 1165-1169.	0.7	82
51	Multiplate whole blood impedance aggregometry: A recent experience. <i>Thrombosis and Haemostasis</i> , 2008, 100, 725-726.	1.8	18
52	Determination of Clopidogrel Main Metabolite in Plasma: A Useful Tool for Monitoring Therapy?. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 84-89.	1.0	42
53	Resistance to Aspirin and Thienopyridines in Diabetes Mellitus and Metabolic Syndrome. <i>Current Vascular Pharmacology</i> , 2008, 6, 313-328.	0.8	30
54	Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. <i>Thrombosis and Haemostasis</i> , 2008, 99, 121-126.	1.8	265
55	Assessment of VerifyNow P2Y ₁₂ Assay Accuracy in Evaluating Clopidogrel-Induced Platelet Inhibition. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 372-378.	1.0	36
56	Point-of-Care Whole Blood Impedance Aggregometry Versus Classical Light Transmission Aggregometry for Detecting Aspirin and Clopidogrel: The Results of a Pilot Study. <i>Anesthesia and Analgesia</i> , 2008, 107, 1798-1806.	1.1	106
59	Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. <i>Thrombosis and Haemostasis</i> , 2008, 99, 161-168.	1.8	71
60	Diabetes mellitus: a prothrombotic state. Implications for outcomes after coronary revascularization. <i>Vascular Health and Risk Management</i> , 2009, 5, 101.	1.0	11
61	Platelet P2Y ₁₂ receptor inhibition by thienopyridines: status and future. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1317-1332.	1.9	20
62	Clinical management of clopidogrel inefficiency by point of care platelet function testing and individual adjustment of anti-platelet therapy – initial experiences. <i>Platelets</i> , 2009, 20, 498-504.	1.1	5

#	ARTICLE	IF	CITATIONS
63	Review: Platelet Function Testing and Implications for Clinical Practice. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2009, 14, 157-169.	1.0	44
64	Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions. <i>Diabetes Care</i> , 2009, 32, 531-540.	4.3	115
65	Clopidogrel plus PPIs—a dangerous combination?. <i>Nature Reviews Cardiology</i> , 2009, 6, 392-394.	6.1	11
66	Personalized medicine and antiplatelet therapy: ready for prime time?. <i>European Heart Journal</i> , 2009, 30, 1943-1963.	1.0	37
67	A clinician's perspective of emerging P2Y12-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes. <i>Platelets</i> , 2009, 20, 302-315.	1.1	3
68	Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel. <i>Circulation</i> , 2009, 119, 2553-2560.	1.6	615
69	Platelet reactivity and nonresponse to dual antiplatelet therapy: A review. <i>Platelets</i> , 2009, 20, 531-538.	1.1	13
71	Test Before You Stop. <i>Archives of Surgery</i> , 2009, 144, 787.	2.3	2
72	Common Variation in the Platelet Receptor <i>P2RY12</i> Gene Is Associated With Residual On-Clopidogrel Platelet Reactivity in Patients Undergoing Elective Percutaneous Coronary Interventions. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 515-521.	5.1	52
73	Aprotinin reduces the antiplatelet effect of clopidogrel. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2009, 9, 178-181.	0.5	10
74	New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?. <i>European Heart Journal</i> , 2009, 30, 1695-1702.	1.0	18
75	Cangrelor in percutaneous coronary intervention. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 137-145.	1.3	3
76	Pharmacogenetics in Hemostasis: Friend or Foe?. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 042-049.	1.5	5
77	Update on Antiplatelet Therapy in Acute Coronary Syndromes. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 13-17.	1.0	1
78	Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. <i>Thrombosis and Haemostasis</i> , 2009, 101, 714-719.	1.8	343
79	Dual Antiplatelet Drug Resistance Is a Risk Factor for Cardiovascular Events after Percutaneous Coronary Intervention. <i>Clinical Chemistry</i> , 2009, 55, 1171-1176.	1.5	21
80	Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 849.	3.8	1,319
81	Clopidogrel-Induced Hepatocellular Injury and Cholestatic Jaundice in an Elderly Patient: Case Report and Review of the Literature. <i>Pharmacotherapy</i> , 2009, 29, 608-612.	1.2	24

#	ARTICLE	IF	CITATIONS
82	Variability in Responsiveness to Oral Antiplatelet Therapy. American Journal of Cardiology, 2009, 103, 27A-34A.	0.7	132
83	Advances in Antiplatelet Therapy: Agents in Clinical Development. American Journal of Cardiology, 2009, 103, 40A-51A.	0.7	88
84	Predictors of Heightened Platelet Reactivity Despite Dual-Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2009, 103, 1339-1343.	0.7	138
85	Relation of Genetic Polymorphisms in the Cytochrome P450 Gene With Clopidogrel Resistance After Drug-Eluting Stent Implantation in Koreans. American Journal of Cardiology, 2009, 104, 46-51.	0.7	93
86	Predictive Values of Post-Treatment Adenosine Diphosphate-Induced Aggregation and Vasodilator-Stimulated Phosphoprotein Index for Stent Thrombosis After Acute Coronary Syndrome in Clopidogrel-Treated Patients. American Journal of Cardiology, 2009, 104, 1078-1082.	0.7	66
87	A Comparison of Clopidogrel Responsiveness in Patients With Versus Without Chronic Renal Failure. American Journal of Cardiology, 2009, 104, 1292-1295.	0.7	116
88	Antiplatelet drug response variability and the role of platelet function testing: A practical guide for interventional cardiologists. Catheterization and Cardiovascular Interventions, 2009, 73, 1-14.	0.7	36
89	Acknowledging a failed strategy. Catheterization and Cardiovascular Interventions, 2009, 73, 871-873.	0.7	2
90	Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. Clinical Research in Cardiology, 2009, 98, 533-540.	1.5	36
91	Oral Antiplatelet Therapy for Acute and Chronic Management of NSTEMI ACS: Residual Ischemic Risk and Opportunities for Improvement. Cardiovascular Drugs and Therapy, 2009, 23, 489-499.	1.3	6
92	Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients. Journal of Thrombosis and Thrombolysis, 2009, 28, 151-155.	1.0	14
93	Prasugrel: Clinical development and therapeutic application. Advances in Therapy, 2009, 26, 999-1011.	1.3	10
94	Choice of DES: A European Clinician's Perspective. Journal of Interventional Cardiology, 2009, 22, .	0.5	0
95	The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. Journal of Thrombosis and Haemostasis, 2009, 7, 1409-1411.	1.9	114
96	Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents. Fundamental and Clinical Pharmacology, 2009, 23, 1-9.	1.0	11
97	Antiplatelet "resistance"™ and "nonresponders"™: what do these terms really mean?. Fundamental and Clinical Pharmacology, 2009, 23, 11-18.	1.0	7
98	Clopidogrel response variability: Current status and future directions. Thrombosis and Haemostasis, 2009, 102, 07-14.	1.8	114
99	Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention. Circulation, 2009, 119, 3215-3222.	1.6	213

#	ARTICLE	IF	CITATIONS
100	Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. <i>Thrombosis Research</i> , 2009, 123, 597-603.	0.8	72
101	Effect of increased aspirin dose after Stenting in association with CLOpidogrel: The FIASCO randomized study. <i>Thrombosis Research</i> , 2009, 124, 33-36.	0.8	2
102	Impact of P2Y12 Inhibitory Effects Induced by Clopidogrel on Platelet Procoagulant Activity in Type 2 Diabetes Mellitus Patients. <i>Thrombosis Research</i> , 2009, 124, 318-322.	0.8	37
103	Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions – Limited inhibition of the P2Y12 receptor. <i>Thrombosis Research</i> , 2009, 124, 193-198.	0.8	7
104	Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel. <i>Thrombosis Research</i> , 2009, 124, 546-553.	0.8	16
105	Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-st-segment elevation acute coronary syndrome. <i>Thrombosis Research</i> , 2009, 124, 678-682.	0.8	3
106	Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial. <i>American Heart Journal</i> , 2009, 157, 818-824.e1.	1.2	110
107	Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1101-1109.	1.2	431
108	Interaction Between Cigarette Smoking and Clinical Benefit of Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1273-1278.	1.2	113
109	Pharmacogenetics in Cardiovascular Antithrombotic Therapy. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1041-1057.	1.2	92
110	Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1149-1153.	1.2	212
111	The Relative Efficacy and Safety of Clopidogrel in Women and Men. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1935-1945.	1.2	119
112	Hunting for the ‘Sweet Spot’ in P2Y12 Receptor Blockade. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1447-1449.	1.2	3
113	Variable platelet responsiveness to aspirin and clopidogrel: role of platelet function and genetic polymorphism testing. <i>Translational Research</i> , 2009, 154, 309-313.	2.2	13
115	Post-Treatment Platelet Reactivity Predicts Long-Term Adverse Events Better Than the Response to Clopidogrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 126-135.	0.4	4
116	Prasugrel. <i>Drugs</i> , 2009, 69, 1707-1726.	4.9	19
117	Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study. <i>Journal of Translational Medicine</i> , 2009, 7, 42.	1.8	10
118	Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin. <i>Platelets</i> , 2009, 20, 250-259.	1.1	42

#	ARTICLE	IF	CITATIONS
119	Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 2009, 7, 361-369.	0.6	12
120	Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. European Heart Journal, 2009, 30, 1744-1752.	1.0	231
121	Potential Interaction between Clopidogrel and Proton Pump Inhibitors. American Journal of Cardiovascular Drugs, 2009, 9, 353-359.	1.0	4
122	Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet, The, 2009, 373, 309-317.	6.3	864
123	Risk of combining PPIs with thienopyridines: fact or fiction?. Lancet, The, 2009, 374, 952-954.	6.3	37
126	Cytochrome P-450 Polymorphisms and Response to Clopidogrel. New England Journal of Medicine, 2009, 360, 354-362.	13.9	2,209
127	Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 375-388.	2.2	53
128	Prasugrel: A Novel Platelet ADP P2Y ₁₂ Receptor Antagonist. Cardiovascular Therapeutics, 2009, 27, 194-198.	1.1	6
129	Ticagrelor: The First Reversibly Binding Oral P2Y ₁₂ Receptor Antagonist. Cardiovascular Therapeutics, 2009, 27, 259-274.	1.1	304
130	Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics, 2009, 10, 1799-1817.	0.6	100
131	Cangrelor: a review on its mechanism of action and clinical development. Expert Review of Cardiovascular Therapy, 2009, 7, 1195-1201.	0.6	81
132	Hostility and Platelet Reactivity in Individuals Without a History of Cardiovascular Disease Events. Psychosomatic Medicine, 2009, 71, 741-747.	1.3	21
133	Variability in Platelet Response to the Antiplatelet Agents Aspirin and Clopidogrel. Critical Pathways in Cardiology, 2009, 8, 20-28.	0.2	9
134	Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. Thrombosis and Haemostasis, 2009, 102, 248-257.	1.8	359
135	Current guidance on the management Of acute coronary syndrome. British Journal of Nursing, 2009, 18, 1292-1298.	0.3	2
137	Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal, 2009, 30, 1753-1763.	1.0	226
138	Emerging P2Y ₁₂ Receptor Antagonists: Role in Coronary Artery Disease. Current Vascular Pharmacology, 2010, 8, 93-101.	0.8	6
139	Genetic predisposition to adverse drug reactions in the intensive care unit. Critical Care Medicine, 2010, 38, S106-S116.	0.4	52

#	ARTICLE	IF	CITATIONS
140	Pantoprazole Does Not Influence the Antiplatelet Effect of Clopidogrel-A Whole Blood Aggregometry Study After Coronary Stenting. <i>Journal of Cardiovascular Pharmacology</i> , 2010, 56, 91-97.	0.8	48
141	A New Era for Antiplatelet Therapy in Patients With Acute Coronary Syndrome. <i>American Journal of the Medical Sciences</i> , 2010, 340, 407-411.	0.4	8
142	Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. <i>Thrombosis and Haemostasis</i> , 2010, 104, 626-632.	1.8	28
143	Recurrence of Acute Myocardial Infarction in Patients Discharged on Clopidogrel and a Proton Pump Inhibitor After Stent Placement for Acute Myocardial Infarction. <i>Clinical Cardiology</i> , 2010, 33, 168-171.	0.7	49
144	Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y ₁₂ receptor antagonist. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 151-158.	0.6	76
146	Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y ₁₂ receptor antagonist, in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 487-496.	0.8	174
147	Enhanced platelet activation following coronary stent implantation in patients on hemodialysis. <i>Cardiovascular Intervention and Therapeutics</i> , 2010, 25, 72-77.	1.2	7
148	Poor response to clopidogrel: current and future options for its management. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 319-331.	1.0	53
149	Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y ₁₂ assay. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 486-495.	1.0	32
150	Antiplatelet therapy for atherothrombotic disease: How can we improve the outcomes?. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 240-249.	1.0	1
151	Old and New Molecular Mechanisms Associated with Platelet Resistance to Antithrombotics. <i>Pharmaceutical Research</i> , 2010, 27, 2365-2373.	1.7	17
153	Tratamiento antitrombótico en diabéticos con síndrome coronario agudo. <i>Revista Espanola De Cardiologia Suplementos</i> , 2010, 10, 42-48.	0.2	0
154	Tratamiento antitrombótico en situaciones de alto riesgo. Casos clínicos. <i>Revista Espanola De Cardiologia Suplementos</i> , 2010, 10, 59-65.	0.2	0
155	Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. , 2010, 125, 249-259.		39
156	Impact of Acute Coronary Syndromes on Two-Year Clinical Outcomes in Patients With Unprotected Left Main Coronary Artery Stenosis Treated With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2010, 105, 174-178.	0.7	11
157	Relation of Endothelial Function to Residual Platelet Reactivity After Clopidogrel in Patients With Stable Angina Pectoris Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2010, 105, 333-338.	0.7	35
158	Relation of Proton Pump Inhibitor Use After Percutaneous Coronary Intervention With Drug-Eluting Stents to Outcomes. <i>American Journal of Cardiology</i> , 2010, 105, 833-838.	0.7	73
159	Clopidogrel and Cardiac Operations. <i>Annals of Thoracic Surgery</i> , 2010, 90, 1391.	0.7	1

#	ARTICLE	IF	CITATIONS
160	Antiplatelet Agents in Acute Coronary Syndromes. <i>Current Problems in Cardiology</i> , 2010, 35, 123-170.	1.1	16
161	High Residual Platelet Reactivity After Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 35-40.	1.1	65
162	Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 731-741.	1.1	78
163	Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 250-256.	1.9	305
164	Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1685-1693.	1.9	121
165	Cilostazol augments the inhibition of platelet aggregation in clopidogrel low-responders. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2577-2579.	1.9	14
166	Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 65-77.	1.1	127
167	Antiplatelet therapies for the treatment of cardiovascular disease. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 154-169.	21.5	329
168	Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor. <i>Journal of Blood Medicine</i> , 2010, 1, 197.	0.7	36
169	Pre-Procedural Platelet Reactivity After Clopidogrel Loading in Korean Patients Undergoing Scheduled Percutaneous Coronary Intervention. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010, 17, 1122-1131.	0.9	15
170	Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2010, 103, 774-779.	1.8	9
171	The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance?. <i>Clinical Pharmacology: Advances and Applications</i> , 2010, 2, 155.	0.8	4
172	Os stents farmacolÃ³gicos sÃ£o seguros e eficazes em longo prazo?. <i>Arquivos Brasileiros De Cardiologia</i> , 2010, 95, 663-670.	0.3	3
173	ADP-receptor blockade: A case for personalised pharmacotherapy?. <i>Thrombosis and Haemostasis</i> , 2010, 103, 496-506.	1.8	17
174	Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban. <i>Journal of Blood Medicine</i> , 2010, 1, 61.	0.7	2
175	Comparison of Platelet P2Y12 ADP Receptor-Mediated Pathway Inhibition in Triple Versus Dual Antiplatelet Therapy as Assessed by VASP-Phosphorylation in Japanese Patients Undergoing Coronary Stenting. <i>International Heart Journal</i> , 2010, 51, 303-307.	0.5	5
176	Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. <i>Annals of Medicine</i> , 2010, 42, 19-35.	1.5	23
177	Platelet function testing and risk of bleeding complications. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1128-1135.	1.8	97

#	ARTICLE	IF	CITATIONS
179	Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing a one-stop hybrid coronary revascularization. <i>Platelets</i> , 2010, 21, 183-190.	1.1	16
180	CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. <i>European Heart Journal</i> , 2010, 31, 3046-3053.	1.0	138
181	Pharmacogenetics guided anticoagulation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, S119-27.	1.4	0
183	Pharmacodynamic Effects of Concomitant Versus Staggered Clopidogrel and Omeprazole Intake. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 436-441.	1.4	58
184	Oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention: Balancing efficacy and bleeding risk. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, S7-S17.	0.5	4
185	Nonresponders to clopidogrel: pharmacokinetics and interactions involved. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2391-2403.	0.9	13
186	Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1821.	3.8	980
187	Anti-thrombotic medications for the neurointerventionist: aspirin and clopidogrel. <i>Journal of NeuroInterventional Surgery</i> , 2010, 2, 44-49.	2.0	28
188	VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation. <i>Platelets</i> , 2010, 21, 94-100.	1.1	17
189	Platelet thrombin receptor antagonism and atherothrombosis. <i>European Heart Journal</i> , 2010, 31, 17-28.	1.0	214
190	Review article: Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease. <i>Diabetes and Vascular Disease Research</i> , 2010, 7, 274-288.	0.9	8
191	Considerations in patients receiving oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, S18-S24.	0.5	1
192	Decision making after aspirin, clopidogrel and GPIIb/IIIa inhibitor use. <i>Multimedia Manual of Cardiothoracic Surgery: MMCTS / European Association for Cardio-Thoracic Surgery</i> , 2010, 2010, mmcts.2010.004580.	0.5	1
194	Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization. <i>Biomarkers in Medicine</i> , 2010, 4, 421-434.	0.6	4
195	The Relationship Between Inflammation, Platelet Activation and Antiplatelet Resistance. <i>Inflammation and Allergy: Drug Targets</i> , 2010, 9, 364-381.	1.8	4
196	Duration of Clopidogrel Therapy with Drug-Eluting Stents. <i>New England Journal of Medicine</i> , 2010, 363, 488-490.	13.9	0
197	Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. <i>European Heart Journal</i> , 2010, 31, 1205-1211.	1.0	75
198	Benefits of and safety concerns associated with drug-eluting coronary stents. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 449-470.	0.6	24

#	ARTICLE	IF	CITATIONS
199	Reducing Cardiac Ischemic Events in Patients with ACS: Prasugrel versus Clopidogrel. <i>Postgraduate Medicine</i> , 2010, 122, 198-200.	0.9	1
200	Interaction between clopidogrel and proton-pump inhibitors. <i>Expert Review of Clinical Pharmacology</i> , 2010, 3, 89-102.	1.3	1
201	Elinogrel: pharmacological principles, preclinical and early phase clinical testing. <i>Future Cardiology</i> , 2010, 6, 445-453.	0.5	51
202	Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1557-1567.	1.9	10
203	The Coronary Collier. <i>Journal of the American College of Cardiology</i> , 2010, 56, 318-319.	1.2	0
204	Impact of Chronic Kidney Disease on Platelet Function Profiles in Diabetes Mellitus Patients With Coronary Artery Disease Taking Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1139-1146.	1.2	193
205	Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration. <i>Journal of the American College of Cardiology</i> , 2010, 56, 134-143.	1.2	348
206	Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1017-1023.	1.2	160
207	Clopidogrel and Endothelial Injury After Percutaneous Coronary Interventions. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1032-1033.	1.2	4
208	Platelet Aggregation and Its Association With Stent Thrombosis and Bleeding in Clopidogrel-Treated Patients. <i>Journal of the American College of Cardiology</i> , 2010, 56, 317-318.	1.2	196
209	Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1456-1462.	1.2	339
210	Long-Term Clinical Outcome Based on Aspirin and Clopidogrel Responsiveness Status After Elective Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1447-1455.	1.2	118
211	Coronary Stents. <i>Journal of the American College of Cardiology</i> , 2010, 56, S1-S42.	1.2	447
212	Clopidogrel response: Head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. <i>Archives of Cardiovascular Diseases</i> , 2010, 103, 39-45.	0.7	53
213	Effect of Intrinsic and Extrinsic Factors on the Clinical Pharmacokinetics and Pharmacodynamics of Prasugrel. <i>Clinical Pharmacokinetics</i> , 2010, 49, 777-798.	1.6	54
214	Platelet Adenosine Diphosphate P2Y12 Receptor Antagonism: Benefits and Limitations of Current Treatment Strategies and Future Directions. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 60-76.	0.4	36
215	Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2010, 31, 3006-3016.	1.0	389
216	Antiplatelet therapy and vascular disease: an update. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 249-275.	1.0	16

#	ARTICLE	IF	CITATIONS
217	The treatment of clopidogrel resistance: Triple antiplatelet therapy and future directions. <i>International Journal of Cardiology</i> , 2010, 144, 79-82.	0.8	4
218	A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150mg/day versus 75mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study. <i>Thrombosis Research</i> , 2010, 125, 309-314.	0.8	44
219	Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: The prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronary revascularisation). <i>Thrombosis Research</i> , 2010, 126, e397-e399.	0.8	3
220	Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome. <i>Thrombosis Research</i> , 2010, 126, e400-e402.	0.8	24
221	Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. <i>Thrombosis and Haemostasis</i> , 2010, 103, 151-159.	1.8	126
222	Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis. <i>American Heart Journal</i> , 2010, 160, 543-551.	1.2	188
223	Novel antiplatelet therapy. <i>American Heart Journal</i> , 2010, 160, 595-604.	1.2	19
224	Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. <i>American Heart Journal</i> , 2010, 160, 506-512.	1.2	147
225	REVIEW: Stent Thrombosis – Risk Assessment and Prevention. <i>Cardiovascular Therapeutics</i> , 2010, 28, e92-100.	1.1	18
227	Clopidogrel Resistance is Associated with Long-Term Thrombotic Events in Patients Implanted with Drug-Eluting Stents. <i>Drugs in R and D</i> , 2010, 10, 219-224.	1.1	15
228	Individual Variability of Response to Antiplatelet Therapy is an Important Determinant of Adverse Clinical Outcome. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2010, 17, 121-130.	1.0	3
229	Platelet P2Y12 Receptor Inhibition. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 217-226.	1.0	24
230	Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity. <i>Platelets</i> , 2010, 21, 1-10.	1.1	11
231	Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 119-133.	1.9	14
232	Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. <i>Pharmacogenomics Journal</i> , 2011, 11, 199-206.	0.9	152
233	Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. <i>Platelets</i> , 2011, 22, 98-102.	1.1	23
234	Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 124, 1132-1137.	1.6	381
235	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2011, 57, 672-684.	1.2	457

#	ARTICLE	IF	CITATIONS
236	Clopidogrelâ€™Drug Interactions. Journal of the American College of Cardiology, 2011, 57, 1251-1263.	1.2	178
237	Unraveling Myths of Platelet Function and Genetic Testing. Journal of the American College of Cardiology, 2011, 57, 2484-2486.	1.2	9
238	Impact of Insulin Receptor Substrate-1 Genotypes on Platelet Reactivity and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Journal of the American College of Cardiology, 2011, 58, 30-39.	1.2	58
239	Impact of Pentoxifylline on Platelet Function Profiles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel. JACC: Cardiovascular Interventions, 2011, 4, 905-912.	1.1	17
240	Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert Opinion on Pharmacotherapy, 2011, 12, 1285-1295.	0.9	42
241	The Interaction Between Proton Pump Inhibitors and Clopidogrel and Upper Gastrointestinal Bleeding. Gastrointestinal Endoscopy Clinics of North America, 2011, 21, 637-656.	0.6	15
242	Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. Thrombosis and Haemostasis, 2011, 106, 571-584.	1.8	188
243	Clopidogrel Response Variability and Its Correlation with Early Recurrent Cardiovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention. Pharmacology, 2011, 87, 321-330.	0.9	3
244	Genetic determinants of on-clopidogrel high platelet reactivity. Platelets, 2011, 22, 399-407.	1.1	48
245	Clopidogrel Resistance: Case reports of CYP2C19 gene variants in suspected coronary stent thrombosis. Heart Lung and Circulation, 2011, 20, 657-658.	0.2	3
246	Antiplatelet effects of Cyperus rotundus and its component (+)-nootkatone. Journal of Ethnopharmacology, 2011, 135, 48-54.	2.0	82
247	The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. Thrombosis Research, 2011, 127, 23-28.	0.8	54
248	Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. Thrombosis Research, 2011, 128, e130-e136.	0.8	29
249	In-vitro assessment of platelet function. Transfusion and Apheresis Science, 2011, 44, 305-319.	0.5	57
250	A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes Mellitus (OPTIMUS)-3 Trial. European Heart Journal, 2011, 32, 838-846.	1.0	178
251	Pharmacogenetics, Pharmacogenomics, and Individualized Medicine. Pharmacological Reviews, 2011, 63, 437-459.	7.1	418
252	Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. Future Cardiology, 2011, 7, 381-402.	0.5	13
253	Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease. Thrombosis and Haemostasis, 2011, 105, 730-732.	1.8	34

#	ARTICLE	IF	CITATIONS
254	Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. <i>Thrombosis and Haemostasis</i> , 2011, 106, 1149-1157.	1.8	29
255	Platelet function variability and non-genetic causes. <i>Thrombosis and Haemostasis</i> , 2011, 105, S60-S66.	1.8	30
257	Early determination of clopidogrel responsiveness by platelet reactivity index identifies patients at risk for cardiovascular events after myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2011, 106, 141-148.	1.8	15
258	Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. <i>Thrombosis and Haemostasis</i> , 2011, 106, 253-262.	1.8	37
259	Genomic Medicine and Neurology. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2011, 17, 249-267.	0.4	4
260	Abundance- and Activity-Based Proteomics in Platelet Biology. <i>Current Proteomics</i> , 2011, 8, 216-228.	0.1	5
261	Platelet Inhibition and Surgical Bleeding. <i>Circulation Journal</i> , 2011, 75, 2751-2752.	0.7	1
262	Evaluation of Clopidogrel Resistance in Ischemic Stroke Patients. <i>Internal Medicine</i> , 2011, 50, 31-35.	0.3	27
263	Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011, 18, 431-442.	0.9	46
264	Antiplatelet therapy: thrombin receptor antagonists. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 658-671.	1.1	34
265	Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 697-706.	1.1	43
266	Review article: proton pump inhibitors with clopidogrel - evidence for and against a clinically-important interaction. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 758-767.	1.9	12
267	Clopidogrel 150 vs. 75 mg/day in patients undergoing percutaneous coronary intervention: a meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 627-637.	1.9	10
268	Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 65-74.	2.3	249
269	Individual variability in the disposition of and response to clopidogrel: Pharmacogenomics and beyond. , 2011, 129, 267-289.		52
270	Usefulness of Mean Platelet Volume as a Biomarker for Long-Term Outcomes After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2011, 107, 204-209.	0.7	67
271	Usefulness of High Clopidogrel Maintenance Dose According to CYP2C19 Genotypes in Clopidogrel Low Responders Undergoing Coronary Stenting for Non ST Elevation Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2011, 108, 760-765.	0.7	40
272	Comparison of Platelet Reactivity and Clopidogrel Response in Patients >75 Years Versus <75 Years Undergoing Percutaneous Coronary Intervention for Non-ST-Segment Elevation Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2011, 108, 1411-1416.	0.7	18

#	ARTICLE	IF	CITATIONS
273	Modifying Clopidogrel Maintenance Doses According to Vasodilator-Activated Phosphoprotein Phosphorylation Index Improves Clinical Outcome in Patients With Clopidogrel Resistance. <i>Clinical Cardiology</i> , 2011, 34, 332-338.	0.7	47
274	Personalized vascular medicine: Individualizing drug therapy. <i>Vascular Medicine</i> , 2011, 16, 391-404.	0.8	16
275	Cardiovascular Pharmacogenomics. <i>Circulation Research</i> , 2011, 109, 807-820.	2.0	71
276	Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. <i>Molecular Biology Reports</i> , 2011, 38, 1697-1702.	1.0	44
277	Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. <i>Clinical Research in Cardiology</i> , 2011, 100, 907-914.	1.5	7
278	Current Role of Pharmacogenomics in Cardiovascular Medicine. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2011, 13, 302-312.	0.4	1
279	Effect of cilostazol on optimized standard antiplatelet therapy in a patient with a cytochrome P450 2C19 *2/*2 genotype. <i>Cardiovascular Intervention and Therapeutics</i> , 2011, 26, 79-82.	1.2	2
280	The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel. <i>Thrombosis Journal</i> , 2011, 9, 4.	0.9	28
281	Synthesis, spectroscopic, thermal and biological aspects of drug-based copper(II) complexes. <i>Applied Organometallic Chemistry</i> , 2011, 25, 454-463.	1.7	11
282	Optimizing Platelet Inhibition in Clopidogrel Poor Metabolizers. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 411-414.	1.1	22
283	The optimal pharmacological formula for percutaneous coronary intervention. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1075-1086.	0.9	0
284	Antiplatelet options for secondary prevention in acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1403-1415.	0.6	1
285	Functional testing methods for the antiplatelet effect of P2Y12receptor antagonists. <i>Biomarkers in Medicine</i> , 2011, 5, 43-51.	0.6	11
286	The Role of the Cytochrome P450 Polymorphisms in Clopidogrel Efficacy and Clinical Utility. <i>Current Medicinal Chemistry</i> , 2011, 18, 427-438.	1.2	15
287	Role of Platelet Function Testing in Clinical Practice: Current Concepts and Future Perspectives. <i>Current Drug Targets</i> , 2011, 12, 1836-1847.	1.0	11
288	Does Platelet Function Testing Predict Bleeding?-Pro. <i>Point of Care</i> , 2011, 10, 133-135.	0.5	0
289	Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 561-569.	0.2	34
290	Platelet Biology and Implications for Antiplatelet Therapy in Atherothrombotic Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 371-380.	0.7	10

#	ARTICLE	IF	CITATIONS
291	Evaluation of a Microarray-Based Genotyping Assay for the Rapid Detection of Cytochrome P450 2C19 *2 and *3 Polymorphisms From Whole Blood Using Nanoparticle Probes. American Journal of Clinical Pathology, 2011, 136, 604-608.	0.4	20
292	Pharmacodynamic Evaluation of Pantoprazole Therapy on Clopidogrel Effects. Circulation: Cardiovascular Interventions, 2011, 4, 273-279.	1.4	35
293	Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2011, 305, 1097.	3.8	1,185
294	Applying Platelet Function Testing in Clinical Practice. JAMA - Journal of the American Medical Association, 2011, 306, 1260.	3.8	9
295	A new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD. Therapeutic Advances in Respiratory Disease, 2011, 5, 91-103.	1.0	20
296	P2Y12 Receptor Inhibitors: Integrating Ticagrelor into the Management of Acute Coronary Syndrome. Annals of Pharmacotherapy, 2011, 45, 1151-1156.	0.9	9
297	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting. Circulation: Cardiovascular Interventions, 2011, 4, 522-534.	1.4	103
298	Clopidogrel (Plavix). American Journal of Neuroradiology, 2011, 32, 2002-2004.	1.2	11
299	Responsiveness to P2Y12 receptor inhibitors. Current Opinion in Cardiology, 2011, 26, S31-S37.	0.8	10
300	Platelet-Mediated Thrombosis and Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2011, 4, 629-637.	1.4	7
301	Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitus. Expert Review of Cardiovascular Therapy, 2011, 9, 697-710.	0.6	11
302	Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome. Circulation, 2011, 123, 798-813.	1.6	272
303	Clopidogrel pharmacogenetics: metabolism and drug interactions. Drug Metabolism and Drug Interactions, 2011, 26, 45-51.	0.3	11
304	Pharmacodynamic Effect of Switching Therapy in Patients With High On-Treatment Platelet Reactivity and Genotype Variation With High Clopidogrel Dose Versus Prasugrel. Circulation: Cardiovascular Interventions, 2012, 5, 698-704.	1.4	44
305	Impact of Dual Antiplatelet Therapy with Proton Pump Inhibitors on the Outcome of Patients with Acute Coronary Syndrome Undergoing Drug-Eluting Stent Implantation. ISRN Cardiology, 2012, 2012, 1-8.	1.6	10
306	Current antiplatelet options for NSTEMI-ACS patients. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 935-948.	0.2	5
307	Increased Atherothrombotic Burden in Patients with Diabetes Mellitus and Acute Coronary Syndrome: A Review of Antiplatelet Therapy. Cardiology Research and Practice, 2012, 2012, 1-18.	0.5	26
308	Dental Management of Antiplatelet-Receiving Patients: Is Uninterrupted Antiplatelet Therapy Safe?. Angiology, 2012, 63, 245-247.	0.8	13

#	ARTICLE	IF	CITATIONS
309	Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery. JAMA - Journal of the American Medical Association, 2012, 307, 265-74.	3.8	386
310	The Role of Platelet Reactivity and Genotype Testing in the Prevention of Atherothrombotic Cardiovascular Events Remains Unproven. Circulation, 2012, 125, 1288-1303.	1.6	51
311	Treatment algorithm in patients with NSTEMI and unstable angina. , 2012, , 331-346.		0
312	Clinical Use of Clopidogrel. Current Pharmaceutical Design, 2012, 18, 5224-5239.	0.9	28
313	Overcoming obstacles in pharmacogenomic strategies for antiplatelet drugs: are we RAPID enough?. Pharmacogenomics, 2012, 13, 1105-1108.	0.6	2
314	Acute Coronary Syndromes: Identifying the Appropriate Patient for Prasugrel. Postgraduate Medicine, 2012, 124, 16-28.	0.9	1
315	The Pattern of Platelet Response to Clopidogrel in Iranian Patients After Percutaneous Coronary Intervention. Journal of Clinical Pharmacology, 2012, 52, 1098-1105.	1.0	3
316	Population Pharmacokinetic/Pharmacodynamic Modeling of Clopidogrel in Korean Healthy Volunteers and Stroke Patients. Journal of Clinical Pharmacology, 2012, 52, 985-995.	1.0	10
317	The Influence of Omeprazole on Platelet Inhibition of Clopidogrel in Various <i>CYP2C19</i> Mutant Alleles. Genetic Testing and Molecular Biomarkers, 2012, 16, 1293-1297.	0.3	15
318	Description of Response to Aspirin and Clopidogrel in Outpatients With Coronary Artery Disease Using Multiple Electrode Impedance Aggregometry. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 356-363.	0.7	6
319	Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease. Future Cardiology, 2012, 8, 503-511.	0.5	5
320	Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease. Platelets, 2012, 23, 537-551.	1.1	17
321	Current Oral Antiplatelets: Focus Update on Prasugrel. Journal of the American Board of Family Medicine, 2012, 25, 343-349.	0.8	15
322	Cardiovascular Pharmacogenomics: Current Status and Future Directions—Report of a National Heart, Lung, and Blood Institute Working Group. Journal of the American Heart Association, 2012, 1, e000554.	1.6	17
323	Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vascular Health and Risk Management, 2012, 8, 77.	1.0	35
324	High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. European Heart Journal, 2012, 33, 1241-1249.	1.0	127
325	Challenges and Perspectives of Antiplatelet Therapy in Patients with Diabetes Mellitus and Coronary Artery Disease. Current Pharmaceutical Design, 2012, 18, 5273-5293.	0.9	19
326	Pharmacogenetics of Clopidogrel. Current Pharmaceutical Design, 2012, 18, 5309-5327.	0.9	16

#	ARTICLE	IF	CITATIONS
327	Platelet Turnover in Atherothrombotic Disease. <i>Current Pharmaceutical Design</i> , 2012, 18, 5328-5343.	0.9	20
328	Recent Safety Concerns With Proton Pump Inhibitors. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 93-114.	1.1	82
329	Chiral Stability Study of Oral Liquid Clopidogrel Formulations for Infants. <i>Journal of Pharmacy Practice and Research</i> , 2012, 42, 106-110.	0.5	2
331	Impact of Platelet Reactivity to Adenosine Diphosphate Before Implantation of Drug-Eluting Stents on Subsequent Adverse Cardiac Events in Patients With Stable Angina. <i>Circulation Journal</i> , 2012, 76, 641-649.	0.7	8
332	Association of CYP2C19 Genotype With Periprocedural Myocardial Infarction After Uneventful Stent Implantation in Chinese Patients Receiving Clopidogrel Pretreatment. <i>Circulation Journal</i> , 2012, 76, 2773-2778.	0.7	13
333	Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. <i>Lancet, The</i> , 2012, 379, 1705-1711.	6.3	341
334	Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. <i>Heart</i> , 2012, 98, 100-108.	1.2	145
335	2012 Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations. <i>Annals of Thoracic Surgery</i> , 2012, 94, 1761-1781.	0.7	256
336	Clinical scientific notes. <i>Internal Medicine Journal</i> , 2012, 42, 7-8.	0.5	1
337	Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes—insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2012, 164, 334-342.e1.	1.2	53
338	Clinical Pharmacogenomics of Warfarin and Clopidogrel. <i>Journal of Pharmacy Practice</i> , 2012, 25, 428-438.	0.5	13
339	Prasugrel. <i>Advances in Cardiology</i> , 2012, 47, 39-63.	2.6	3
340	Review of ticagrelor in the management of acute coronary syndromes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1315-1325.	1.5	1
341	TRITON and Beyond: New Insights into the Profile of Prasugrel. <i>Cardiovascular Therapeutics</i> , 2012, 30, e174-82.	1.1	17
342	Glycoprotein IIb/IIIa Inhibitors. <i>Cardiovascular Therapeutics</i> , 2012, 30, e242-54.	1.1	23
343	An indirect sandwich ELISA for the determination of agkissacutacin in human serum: Application to pharmacokinetic study in Chinese healthy volunteers. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 70, 396-400.	1.4	7
344	Does the fat cell have something to say to the platelet about keeping thrombosis in check in diabetes?. <i>Translational Research</i> , 2012, 159, 12-14.	2.2	1
345	Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor—a long continuing journey. <i>Indian Heart Journal</i> , 2012, 64, 54-59.	0.2	1

#	ARTICLE	IF	CITATIONS
346	Quelles indications pour le prasugrel et le ticagrelor dans les syndromes coronariens aigus? Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2012, 2012, 31-35.	0.0	0
347	Antiplatelet therapy in acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2012, 13, 27-42.	0.9	4
348	Prior Antiplatelet Use and Cardiovascular Outcomes in Patients Presenting with Acute Coronary Syndromes. American Journal of Cardiovascular Drugs, 2012, 12, 127-135.	1.0	3
349	CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention. Thrombosis Research, 2012, 129, 441-446.	0.8	29
350	Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. Thrombosis Research, 2012, 130, 70-74.	0.8	12
351	Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependant on clopidogrel response. Thrombosis Research, 2012, 130, 198-202.	0.8	17
352	Assessment of Platelet Function in Patients on Antiplatelet Therapy Undergoing Cardiac Surgery: A Review. Heart Lung and Circulation, 2012, 21, 455-462.	0.2	8
353	Outcomes of patients receiving clopidogrel prior to cardiac surgery. International Journal of Cardiology, 2012, 156, 34-40.	0.8	14
354	The Effect of high-dose Clopidogrel treatment in patients with clopidogrel resistance (The EFFICIENT) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.8	54
355	Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. Journal of Thrombosis and Haemostasis, 2012, 10, 2452-2461.	1.9	34
356	The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes. Drugs, 2012, 72, 2087-2116.	4.9	106
357	New Directions in Antiplatelet Therapy. Circulation: Cardiovascular Interventions, 2012, 5, 433-445.	1.4	61
358	Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes. American Heart Journal, 2012, 164, 327-333.	1.2	8
359	Role of Endothelial Shear Stress in Stent Restenosis and Thrombosis. Journal of the American College of Cardiology, 2012, 59, 1337-1349.	1.2	266
360	Influence of Genetic Polymorphisms on the Effect of High- and Standard-Dose Clopidogrel After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2012, 59, 1928-1937.	1.2	127
361	Pharmacodynamic Effects of Prasugrel Dosing Regimens in Patients on Maintenance Prasugrel Therapy. Journal of the American College of Cardiology, 2012, 59, 1681-1687.	1.2	16
362	Platelet Reactivity and Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2012, 60, 378-380.	1.2	0
363	Cigarette Smoking Is Associated With a Dose-Response Effect in Clopidogrel-Treated Patients With Diabetes Mellitus and Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 293-300.	1.1	48

#	ARTICLE	IF	CITATIONS
364	A Therapeutic Window for Platelet Reactivity for Patients Undergoing Elective Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 281-289.	1.1	82
365	CYP2C19*2 and *17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1280-1287.	1.1	92
366	Coagulation management in patients undergoing mechanical circulatory support. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2012, 26, 179-198.	1.7	77
367	Synthesis and inÂvitro stability of nucleoside 5â€²-phosphonate derivatives. <i>European Journal of Medicinal Chemistry</i> , 2012, 54, 202-209.	2.6	8
368	Antiplatelet therapy for patients with diabetes mellitus and acute coronary syndrome. <i>Primary Care Diabetes</i> , 2012, 6, 167-177.	0.9	10
369	Safety profile and bleeding risk of ticagrelor compared with clopidogrel. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 959-967.	1.0	8
370	Control of Oxidative Posttranslational Cysteine Modifications: From Intricate Chemistry to Widespread Biological and Medical Applications. <i>Chemical Research in Toxicology</i> , 2012, 25, 588-604.	1.7	86
371	Pharmacokinetic and Pharmacodynamic Effects of Elinogrel. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 347-356.	1.4	33
373	Impact of Platelet Function Test on Platelet Responsiveness and Clinical Outcome After Coronary Stent Implantation: Platelet Responsiveness and Clinical Outcome. <i>Korean Circulation Journal</i> , 2012, 42, 382.	0.7	11
374	Stent Thrombosis: Incidence, Predictors and New Technologies. <i>Thrombosis</i> , 2012, 2012, 1-12.	1.4	53
375	Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus. <i>Thrombosis and Haemostasis</i> , 2012, 108, 930-936.	1.8	13
376	Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y12 inhibition. <i>Thrombosis and Haemostasis</i> , 2012, 107, 388-395.	1.8	20
377	Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response. <i>Clinical Pharmacology: Advances and Applications</i> , 2012, 4, 13.	0.8	11
378	A Comparison of <sc>INNOVANCE</sc>Â® <sc>PFA P</sc>2<sc>Y</sc> and <sc>V</sc>erify<sc>N</sc>ow <sc>P</sc>2<sc>Y</sc>12 Assay for the Assessment of Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of Clinical Laboratory Analysis</i> . 2012, 26, 262-266.	0.9	13
379	Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drugâ€eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 361-367.	0.7	30
380	Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. <i>Pharmacogenomics</i> , 2012, 13, 465-475.	0.6	29
381	Recent advances in the pharmacogenetics of clopidogrel. <i>Human Genetics</i> , 2012, 131, 653-664.	1.8	26
382	Genomic medicine in the prevention and treatment of atherosclerotic cardiovascular disease. <i>Personalized Medicine</i> , 2012, 9, 395-404.	0.8	3

#	ARTICLE	IF	CITATIONS
383	Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 44-55.	1.0	131
384	Platelet Function and Inhibition in Ischemic Heart Disease. <i>Current Cardiology Reports</i> , 2012, 14, 457-467.	1.3	15
385	Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant?. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 19-26.	1.0	15
386	The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. <i>Biochemical Pharmacology</i> , 2012, 83, 903-908.	2.0	31
387	Association of Estimated GFR With Platelet Inhibition in Patients Treated With Clopidogrel. <i>American Journal of Kidney Diseases</i> , 2012, 59, 777-785.	2.1	52
388	Coronary artery bypass graft surgery up-regulates genes involved in platelet aggregation. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 557-563.	1.9	12
389	Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome. <i>Journal of Cardiovascular Translational Research</i> , 2012, 5, 41-51.	1.1	4
390	Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 137-142.	1.0	55
391	Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: Impact of high on-treatment platelet reactivity and diabetes mellitus status. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 42-49.	0.7	18
392	Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 309-317.	0.8	55
393	Comparison of High-Resolution Melting Analysis, TaqMan Allelic Discrimination Assay, and Sanger Sequencing for Clopidogrel Efficacy Genotyping in Routine Molecular Diagnostics. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 600-606.	1.2	22
394	Rationale and Design of the On-treatment PLatelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) Randomized Trial. <i>Journal of Interventional Cardiology</i> , 2013, 26, 221-227.	0.5	3
395	Platelet Function Profiles in Patients with Diabetes Mellitus. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 329-345.	1.1	46
396	Influence of Platelet Reactivity on Clinical Outcome of Patients with Stable Coronary Artery Disease. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 346-354.	1.1	3
397	CYP-Mediated Pharmacologic Interference with Optimal Platelet Inhibition. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 404-410.	1.1	6
398	Mean platelet volume as a predictor for long-term outcome after percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 469-474.	1.0	20
399	Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 223-232.	1.0	31
400	Thrombin Receptor Antagonism in Antiplatelet Therapy. <i>Cardiology and Therapy</i> , 2013, 2, 57-68.	1.1	10

#	ARTICLE	IF	CITATIONS
401	Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know. Expert Review of Cardiovascular Therapy, 2013, 11, 975-984.	0.6	4
402	Clinical Implications of Very Low On-Treatment Platelet Reactivity in Patients Treated With Thienopyridine. JACC: Cardiovascular Interventions, 2013, 6, 854-863.	1.1	67
403	Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome. American Journal of Cardiology, 2013, 111, 439-444.	0.7	9
404	An evidence-based review of current anti-platelet options for STEMI patients. International Journal of Cardiology, 2013, 166, 294-303.	0.8	11
405	Prevençã³n secundaria en el paciente coronario. EMC - Tratado De Medicina, 2013, 17, 1-8.	0.0	0
406	First experience of a bioresorbable vascular scaffold implantation in left main stenosis. International Journal of Cardiology, 2013, 168, 1566-1568.	0.8	13
407	Predictors of long-term high on-treatment platelet reactivity in clopidogrel-treated patients undergoing coronary stenting for acute coronary syndrome. International Journal of Cardiology, 2013, 168, 1565-1566.	0.8	2
408	Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. International Journal of Cardiology, 2013, 168, 523-528.	0.8	21
409	Glycoprotein IIb-IIIa inhibitors â€“ Do we still need them?. Indian Heart Journal, 2013, 65, 260-263.	0.2	5
410	Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. Journal of Thrombosis and Thrombolysis, 2014, 38, 127-36.	1.0	16
411	Antiplatelet therapy at the time of coronary artery bypass grafting: a multicentre cohort study. European Journal of Cardio-thoracic Surgery, 2013, 44, e133-e140.	0.6	36
412	Routine Assessment of On-Clopidogrel Platelet Reactivity and Gene Polymorphisms in Predicting Clinical Outcome Following Drug-Eluting Stent Implantation in Patients With Stable Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 1166-1175.	1.1	49
413	Clinical consequences of aspirin and clopidogrel resistance: an overview. Acta Neurologica Scandinavica, 2013, 128, 213-219.	1.0	31
414	Dynamic changes and associated factors of clopidogrel resistance in patients after cerebral infarction. Journal of Neurology, 2013, 260, 2928-2937.	1.8	10
415	Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf,50 182 T 792-798.	0.7	12
416	Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects. Archives of Cardiovascular Diseases, 2013, 106, 517-527.	0.7	94
417	Influence of genetic and non-genetic factors on the plasma concentrations of the clopidogrel metabolite (SR26334) among Chinese patients. Clinica Chimica Acta, 2013, 416, 50-53.	0.5	3
418	Effect of the CYP2C19*2 and *3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. European Journal of Clinical Pharmacology, 2013, 69, 1103-1112.	0.8	59

#	ARTICLE	IF	CITATIONS
419	PAR-1 antagonists: current state of evidence. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 1-9.	1.0	15
420	Suboptimal response to clopidogrel and the effect of prasugrel in acute coronary syndromes. <i>International Journal of Cardiology</i> , 2013, 167, 995-999.	0.8	11
421	Switching From Prasugrel to Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 166-168.	1.1	8
422	The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel. <i>International Journal of Cardiology</i> , 2013, 168, 1594-1596.	0.8	14
423	Individualisation du traitement antiplaquettaire : quel est l'impact du monitoring plaquettaire ?. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2013, 2013, 35-41.	0.0	0
424	Platelet Function and Genetic Testing. <i>Journal of the American College of Cardiology</i> , 2013, 62, S21-S31.	1.2	28
425	The role of diastolic filling in preserving left ventricular stroke volume – An MRI study. <i>International Journal of Cardiology</i> , 2013, 168, 1596-1598.	0.8	4
426	The nuances of new antiplatelet drugs in acute coronary syndrome. <i>Journal of Indian College of Cardiology</i> , 2013, 3, 16-23.	0.1	1
427	Comparison of Antiplatelet Efficacy and Tolerability of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients After Percutaneous Coronary Intervention: A Prospective, Multicenter, Randomized, Open-Label, Phase IV, Noninferiority Trial. <i>Clinical Therapeutics</i> , 2013, 35, 28-37.e4.	1.1	8
428	Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial. <i>International Journal of Cardiology</i> , 2013, 167, 1632-1637.	0.8	7
429	Effectiveness of switching –hyper responders– from Prasugrel to Clopidogrel after acute coronary syndrome: The POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study. <i>International Journal of Cardiology</i> , 2013, 168, 5004-5005.	0.8	15
431	Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests. <i>International Journal of Cardiology</i> , 2013, 166, 126-131.	0.8	27
432	Aspirin, Platelet P2Y12 Receptor Inhibitors, and Other Oral Antiplatelets. <i>Interventional Cardiology Clinics</i> , 2013, 2, 527-535.	0.2	8
433	Chronic kidney disease – Is it a true risk factor of reduced clopidogrel efficacy in elderly patients with stable coronary artery disease?. <i>Thrombosis Research</i> , 2013, 131, 218-224.	0.8	8
434	Dual antiplatelet therapy in patients with diabetes mellitus: special considerations. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 307-317.	0.6	6
435	Platelet Responsiveness to Clopidogrel Treatment After Peripheral Endovascular Procedures. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2428-2434.	1.2	64
436	The discovery and development of prasugrel. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 897-905.	2.5	7
437	Suboptimal response to clopidogrel: A genetic risk factor for recurrent ischaemic stroke. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 767-770.	0.8	9

#	ARTICLE	IF	CITATIONS
438	Platelet Function Monitoring and Clopidogrel. <i>Current Cardiology Reports</i> , 2013, 15, 321.	1.3	9
439	Pharmacogenomics of Anti-platelet and Anti-coagulation Therapy. <i>Current Cardiology Reports</i> , 2013, 15, 381.	1.3	9
440	Platelet biology: the role of shear. <i>Expert Review of Hematology</i> , 2013, 6, 205-212.	1.0	12
441	Antiplatelet and Anticoagulant Therapy for Atherothrombotic Disease: The Role of Current and Emerging Agents. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 233-250.	1.0	36
442	Clopidogrel Resistance Is Associated with Thromboembolic Complications in Patients Undergoing Neurovascular Stenting. <i>American Journal of Neuroradiology</i> , 2013, 34, 716-720.	1.2	134
443	Antiplatelet therapy: new pharmacological agents and changing paradigms. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 316-329.	1.9	61
444	Effect of CYP2C19*2 and *17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications. <i>American Journal of Cardiology</i> , 2013, 111, 985-990.	0.7	59
445	Triple versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Adding Cilostazol to Aspirin and Clopidogrel?. <i>Cardiology</i> , 2013, 126, 233-243.	0.6	11
446	Hemorrhagic complications with prasugrel therapy for vascular neurointerventional procedures. <i>Journal of NeuroInterventional Surgery</i> , 2013, 5, 344-345.	2.0	4
447	Ticagrelor: A new antiplatelet drug for acute coronary syndromes. <i>Annals of Tropical Medicine and Public Health</i> , 2013, 6, 14.	0.1	1
448	C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 321-326.	0.5	16
449	Characteristics of new P2Y12 inhibitors. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, S22-S30.	0.6	4
450	Identifying responsiveness to oral P2Y12 receptor blockers. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, S8-S15.	0.6	4
451	Effect on Platelet Reactivity From a Prasugrel Loading Dose After a Clopidogrel Loading Dose Compared With a Prasugrel Loading Dose Alone. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 567-574.	1.4	42
452	Clopidogrel and warfarin pharmacogenetic tests. <i>Current Opinion in Cardiology</i> , 2013, 28, 305-314.	0.8	15
453	Pharmacogenomics Study of Clopidogrel by RFLP based Genotyping of CYP2C19 in Cardiovascular Disease Patients in North-East Population of India. <i>Journal of Pharmacogenomics & Pharmacoproteomics</i> , 2013, 05, .	0.2	2
454	Pharmacologic Options for Treatment of Ischemic Disease. , 2013, , 83-130.		4
455	Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin. <i>Platelets</i> , 2013, 24, 145-150.	1.1	26

#	ARTICLE	IF	CITATIONS
456	Cangrelor: a review on pharmacology and clinical trial development. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1279-1291.	0.6	52
457	Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?. <i>Journal of Human Genetics</i> , 2013, 58, 339-345.	1.1	28
458	Clinical importance of antiplatelet drugs in cardiovascular diseases. <i>Clinical Hemorheology and Microcirculation</i> , 2013, 53, 81-96.	0.9	24
459	Stroke Prevention: From Available Antiplatelet Drugs to Novel Molecular Targets. <i>Current Drug Targets</i> , 2013, 14, 3-12.	1.0	27
460	Research Highlights: Highlights from the latest articles in antithrombotic and myocardial revascularization strategies in coronary artery disease. <i>Interventional Cardiology</i> , 2013, 5, 253-255.	0.0	0
461	Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching anti-platelet (SWAP) study. <i>Thrombosis and Haemostasis</i> , 2013, 109, 347-355.	1.8	19
462	Adjunctive Cilostazol versus High Maintenance Dose of Clopidogrel in Patients with Hyporesponsiveness to Chronic Clopidogrel Therapy. <i>Yonsei Medical Journal</i> , 2013, 54, 34.	0.9	4
463	Pharmacokinetics of 600 mg loading dose of clopidogrel in patients undergoing percutaneous coronary intervention. <i>African Journal of Pharmacy and Pharmacology</i> , 2013, 7, 574-584.	0.2	2
464	Efficacy and Safety of Platelet Inhibitors. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2013, 16, 1.	0.9	10
465	High-Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e78549.	1.1	7
466	Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy. <i>PLoS ONE</i> , 2013, 8, e82562.	1.1	198
467	Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department. <i>Vascular Health and Risk Management</i> , 2013, 9, 187.	1.0	10
468	Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar. <i>Vascular Health and Risk Management</i> , 2014, 10, 177.	1.0	13
469	ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome. <i>European Heart Journal Supplements</i> , 2014, 16, C2-C28.	0.0	2
470	Clopidogrel responsiveness in chronic kidney disease patients with acute coronary syndrome. <i>Dicle Medical Journal</i> , 2014, 41, 34-40.	0.2	0
471	Antiplatelet therapy in acute coronary syndrome: current status and future directions. <i>European Heart Journal Supplements</i> , 2014, 16, C1-C1.	0.0	0
472	Point-of-Care Platelet Reactivity Determination with VerifyNow-P2Y12 following Administration of Clopidogrel or Prasugrel: Data from a Real-World, Clinical Care Inpatient Setting. <i>Hospital Practice (1995)</i> , 2014, 42, 7-15.	0.5	3
473	The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis. <i>Heart</i> , 2014, 100, 192-199.	1.2	21

#	ARTICLE	IF	CITATIONS
474	Impact of Gene Polymorphisms, Platelet Reactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1117-1127.	1.1	38
475	Risk of bleeding and adverse outcomes predicted by thromboelastography platelet mapping in patients taking clopidogrel within 7 days of non-cardiac surgery. <i>British Journal of Surgery</i> , 2014, 101, 1383-1390.	0.1	29
476	Impact of diabetes mellitus and metabolic syndrome on acute and chronic on-clopidogrel platelet reactivity in patients with stable coronary artery disease undergoing drug-eluting stent placement. <i>American Heart Journal</i> , 2014, 168, 940-947.e5.	1.2	17
477	Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 560-563.	1.9	4
479	Effects of Cytochrome P450 2C19 and Paraoxonase 1 Polymorphisms on Antiplatelet Response to Clopidogrel Therapy in Patients with Coronary Artery Disease. <i>PLoS ONE</i> , 2014, 9, e110188.	1.1	19
480	Benefits From New ADP Antagonists as Compared With Clopidogrel in Patients With Stable Angina or Acute Coronary Syndrome Undergoing Invasive Management. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 63, 339-350.	0.8	64
481	CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2014, 25, 412-420.	0.3	14
482	β_2 -Adrenergic Receptor Polymorphism Potentiates Platelet Reactivity in Patients With Stable Coronary Artery Disease Carrying the Cytochrome P450 2C19*2 Genetic Variant. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1314-1319.	1.1	5
483	Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. <i>Open Heart</i> , 2014, 1, e000068.	0.9	39
484	Prognostic Role of Platelet Reactivity in Patients With Acute Coronary Syndromes. <i>Cardiology in Review</i> , 2014, 22, 313-318.	0.6	6
485	CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 870-878.	0.9	9
486	Impact of Smoking on Long-Term Outcomes in Patients With Atherosclerotic Vascular Disease Treated With Aspirin or Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2014, 63, 769-777.	1.2	47
487	Posttreatment platelet reactivity on clopidogrel is associated with the risk of adverse events after off-pump coronary artery bypass. <i>American Heart Journal</i> , 2014, 167, 818-825.	1.2	8
488	Prevalence of Nonresponsiveness to Aspirin in Patients with Symptomatic Peripheral Arterial Disease Using True Point of Care Testing. <i>CardioVascular and Interventional Radiology</i> , 2014, 37, 631-638.	0.9	16
489	High On-Treatment Platelet Reactivity in Peripheral Endovascular Procedures. <i>CardioVascular and Interventional Radiology</i> , 2014, 37, 559-571.	0.9	6
490	Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 427-434.	1.0	7
491	Rationale for Upstream Dual Antiplatelet Therapy in Non-ST-Segment Elevation Myocardial Infarction. <i>Current Emergency and Hospital Medicine Reports</i> , 2014, 2, 76-89.	0.6	1
492	Impact of Cigarette Smoking on P2Y12 Receptor Binding Activity Before and After Clopidogrel Therapy in Patients with Coronary Artery Disease. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 47-52.	1.1	8

#	ARTICLE	IF	CITATIONS
493	Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1500-1509.	1.2	85
494	Management of Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation in the Setting of Acute Coronary Syndromes or Percutaneous Coronary Interventions. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 113-124.	1.4	67
495	Pharmacodynamic Effects of Cangrelor on Platelet P2Y ₁₂ Receptor-Mediated Signaling in Prasugrel-Treated Patients. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 426-434.	1.1	28
496	Impact of CYP2C19 Polymorphism and Proton Pump Inhibitors on Platelet Reactivity to Clopidogrel and Clinical Outcomes Following Stent Implantation. <i>Thrombosis Research</i> , 2014, 133, 599-605.	0.8	40
497	Pharmacological Treatment of Acute Coronary Syndromes. , 2014, , .		2
498	Impact of Obesity and the Metabolic Syndrome on Response to Clopidogrel or Prasugrel and Bleeding Risk in Patients Treated After Coronary Stenting. <i>American Journal of Cardiology</i> , 2014, 113, 54-59.	0.7	35
499	Clopidogrel resistance: The way forward. <i>Indian Heart Journal</i> , 2014, 66, 530-534.	0.2	51
500	Dual Antiplatelet Therapy in the Anticoagulated Patient Undergoing Percutaneous Coronary Intervention Risks, Benefits, and Unanswered Questions. <i>Current Cardiology Reports</i> , 2014, 16, 548.	1.3	2
501	Interaction of clopidogrel and statins in secondary prevention after cerebral ischaemia – a randomized, double-blind, double-dummy crossover study. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1058-1066.	1.1	7
503	Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness. <i>Medicina (Lithuania)</i> , 2014, 50, 19-27.	0.8	3
504	Aspirin Treatment and Outcomes in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 64, 872-874.	1.2	7
505	Does baseline hematocrit influence the assays of on-treatment platelet reactivity to clopidogrel?. <i>American Heart Journal</i> , 2014, 168, 545-551.	1.2	12
506	Impaired Responsiveness to the Platelet P2Y ₁₂ Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1005-1014.	1.2	155
507	High platelet reactivity is associated with vascular function in patients after percutaneous coronary intervention receiving clopidogrel. <i>International Journal of Cardiology</i> , 2014, 177, 192-196.	0.8	11
508	Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 459-469.	1.0	18
509	Individualized strategy for clopidogrel suspension in patients undergoing off-pump coronary surgery for acute coronary syndrome: A case-control study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 1299-1306.	0.4	28
510	The <i>Operculina macrocarpa</i> (L.) Urb. (jalapa) tincture modulates human blood platelet aggregation. <i>Journal of Ethnopharmacology</i> , 2014, 151, 151-157.	2.0	8
511	Effect of Platelet Reactivity, Endothelial Function, and Inflammatory Status on Outcomes in Patients With Stable Angina Pectoris on Clopidogrel Therapy. <i>American Journal of Cardiology</i> , 2014, 113, 786-792.	0.7	19

#	ARTICLE	IF	CITATIONS
512	Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures - the preclip study: clinical impact and optimal cut-off value of high on treatment platelet reactivity. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, S92.	0.2	2
513	ABCB1 C3435T and CYP2C19*2 polymorphisms in a Palestinian and Turkish population: A pharmacogenetic perspective to clopidogrel. <i>Meta Gene</i> , 2014, 2, 314-319.	0.3	9
514	Platelet Function Testing in Contemporary Clinical and Interventional Practice. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 300.	0.4	34
515	Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2014, 60, 993-1001.	0.6	36
516	Relationship between Smoking and Responsiveness to Clopidogrel in Non-cardiogenic Ischemic Stroke Patients. <i>Internal Medicine</i> , 2014, 53, 2575-2579.	0.3	11
517	Response to Clopidogrel and Its Association with Chronic Kidney Disease in Noncardiogenic Ischemic Stroke Patients. <i>Internal Medicine</i> , 2014, 53, 215-219.	0.3	10
518	Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. <i>Thrombosis and Haemostasis</i> , 2014, 112, 311-322.	1.8	7
519	Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2014, 111, 258-265.	1.8	12
520	Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome. <i>Annals of Internal Medicine</i> , 2014, 160, 221-232.	2.0	84
521	Will cangrelor become the favored agent for acute coronary syndrome treatment?. <i>Interventional Cardiology</i> , 2014, 6, 537-545.	0.0	0
522	Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. <i>American Heart Journal</i> , 2015, 170, 706-714.	1.2	5
523	Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. <i>Scientific Reports</i> , 2015, 5, 13789.	1.6	19
524	Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Japanese Patients With Stable Coronary Artery Disease. <i>Circulation Journal</i> , 2015, 79, 2439-2444.	0.7	22
525	Chloroform fraction of <i>Euphorbia maculata</i> has antiplatelet activity via suppressing thromboxane B2 formation. <i>Molecular Medicine Reports</i> , 2015, 11, 4255-4261.	1.1	6
526	Determination of Genotypes Using a Fully Automated Molecular Detection System. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 805-811.	1.2	3
527	The STIB score: a simple clinical test to predict clopidogrel resistance. <i>Acta Cardiologica</i> , 2015, 70, 516-521.	0.3	14
528	Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease. <i>International Journal of Laboratory Hematology</i> , 2015, 37, 809-818.	0.7	14
529	Influence of CYP2C19 loss-of-function variants on the metabolism of clopidogrel in patients from north-western China. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 308-314.	0.7	16

#	ARTICLE	IF	CITATIONS
530	Low On-treatment Platelet Reactivity Predicts Long-term Risk of Bleeding After Elective PCI. <i>Journal of Interventional Cardiology</i> , 2015, 28, 531-543.	0.5	3
531	Personalized antiplatelet therapy with P2Y ₁₂ receptor inhibitors: benefits and pitfalls. <i>Postępy W Kardiologii Interwencyjnej</i> , 2015, 4, 259-280.	0.1	23
532	Diversity of platelet function and genetic polymorphism in clopidogrel-treated Chinese patients. <i>Genetics and Molecular Research</i> , 2015, 14, 1434-1442.	0.3	11
533	Current Status of Antiplatelet Therapy in Acute Coronary Syndrome. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2015, 13, 40-49.	0.4	8
534	A novel biosensor-based microarray assay for the visualized detection of CYP2C19 \hat{a}^{-2} , \hat{a}^{-3} , \hat{a}^{-4} and \hat{a}^{-5} polymorphisms. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 217-23.	1.4	0
535	Platelet reactivity and antiplatelet management in diabetic patients with coronary artery disease. <i>Interventional Cardiology</i> , 2015, 7, 283-293.	0.0	0
536	Platelet reactivity following high loading doses of clopidogrel in patients undergoing primary percutaneous coronary angioplasty: A pilot study. <i>Clinical Trials and Regulatory Science in Cardiology</i> , 2015, 10, 7-12.	1.0	1
537	Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development. <i>Future Cardiology</i> , 2015, 11, 547-564.	0.5	17
538	Secondary prevention of cardiogenic arterial thromboembolism in the cat: the double-blind, randomized, positive-controlled feline arterial thromboembolism; clopidogrel vs. aspirin trial (FAT) Tj ETQq0 0 0 rgB0.0 Overlock 10 Tf 50	0.5	17
539	Cardiogenic embolism in the cat. <i>Journal of Veterinary Cardiology</i> , 2015, 17, S202-S214.	0.3	11
540	Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel. <i>Clinical Pharmacokinetics</i> , 2015, 54, 147-166.	1.6	137
541	Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia. <i>Vascular Pharmacology</i> , 2015, 65-66, 17-22.	1.0	6
542	Impact of impaired glucose tolerance on clopidogrel response in patients with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 174-181.	1.0	8
543	Differential Impact of Selective Serotonin Reuptake Inhibitors on Platelet Response to Clopidogrel: A Randomized, Double-Blind, Crossover Trial. <i>Pharmacotherapy</i> , 2015, 35, 140-147.	1.2	10
544	Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1983-1995.	0.9	12
545	Obesity and Antiplatelets-Does One Size Fit All?. <i>Thrombosis Research</i> , 2015, 136, 712-716.	0.8	21
546	Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy. <i>Thrombosis Research</i> , 2015, 135, 1081-1086.	0.8	7
547	Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001712.	1.4	16

#	ARTICLE	IF	CITATIONS
548	Defining the Link Between Chronic Kidney Disease, High Platelet Reactivity, and Clinical Outcomes in Clopidogrel-Treated Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002760.	1.4	11
549	A pharmacodynamic comparison of a personalized strategy for anti-platelet therapy versus ticagrelor in achieving a therapeutic window. <i>International Journal of Cardiology</i> , 2015, 197, 318-325.	0.8	15
550	Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future. <i>Drugs</i> , 2015, 75, 1229-1253.	4.9	29
551	Clinical outcomes among patients with extreme obesity undergoing elective coronary revascularization: Evaluation of major complications in contemporary practice. <i>International Journal of Cardiology</i> , 2015, 186, 266-272.	0.8	5
553	Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients?. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 758-761.	1.0	6
554	Impact of a high-fat meal on assessment of clopidogrel-induced platelet inhibition in healthy subjects. <i>Thrombosis Journal</i> , 2015, 13, 3.	0.9	1
555	Determinants of subacute response to clopidogrel: relative impact of CYP2C19 genotype and PGE1/adenylate cyclase signalling. <i>Thrombosis Research</i> , 2015, 136, 308-314.	0.8	8
556	Impact of Intravenous Lysine Acetylsalicylate Versus Oral Aspirin on Prasugrel-Inhibited Platelets. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	11
557	Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 331-339.	1.0	4
558	Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview. <i>Platelets</i> , 2016, 27, 1-12.	1.1	5
559	Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. <i>Lancet, The</i> , 2015, 386, 281-291.	6.3	209
560	Blood cells: an historical account of the roles of purinergic signalling. <i>Purinergic Signalling</i> , 2015, 11, 411-434.	1.1	65
561	Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1315-1324.	0.8	31
562	Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> . 2015, 170, 683-694.e3.	1.2	26
563	Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 267-277.	1.6	22
564	Drug-drug interactions between clopidogrel and novel cardiovascular drugs. <i>European Journal of Pharmacology</i> , 2015, 765, 332-336.	1.7	10
565	Personalized Genomes and Cardiovascular Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a014068-a014068.	2.9	7
566	Molecular mechanism of tanshinone IIA and cryptotanshinone in platelet anti-aggregating effects: an integrated study of pharmacology and computational analysis. <i>FÅ-toterapÅ-Åc</i> , 2015, 100, 174-178.	1.1	68

#	ARTICLE	IF	CITATIONS
567	Association between platelet reactivity and circulating platelet-derived microvesicles in patients with acute coronary syndrome. <i>Platelets</i> , 2015, 26, 467-473.	1.1	25
568	High Clopidogrel Dose in Patients With Chronic Kidney Disease Having Clopidogrel Resistance After Percutaneous Coronary Intervention. <i>Angiology</i> , 2015, 66, 319-325.	0.8	8
569	Novel antiplatelet agents in acute coronary syndrome. <i>Nature Reviews Cardiology</i> , 2015, 12, 30-47.	6.1	299
570	Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1060-1069.	1.8	8
571	The predictive value of multiple electrode platelet aggregometry for postoperative bleeding complications in patients undergoing coronary artery bypass graft surgery. <i>Kardiochirurgia i Torakochirurgia Polska</i> , 2016, 1, 3-9.	0.1	9
572	Evaluation of clopidogrel response variability and identification of the CYP2C19 polymorphism in Mexican patients. <i>Archivos De Cardiologia De Mexico</i> , 2016, 86, 297-304.	0.1	4
573	Stent Thrombosis Patients with Hyporesponsiveness to Clopidogrel, Prasugrel, and Ticagrelor: A Case Series Using Short Thromboelastography. <i>Case Reports in Medicine</i> , 2016, 2016, 1-6.	0.3	9
574	Impaired P2Y12 inhibition by clopidogrel in kidney transplant recipients: results from a cohort study. <i>BMC Nephrology</i> , 2016, 17, 58.	0.8	1
575	In Vitro Effects of Pantoprazole on Platelet Aggregation in Blood Samples From Clopidogrel and Aspirin-treated Patients. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 68, 191-195.	0.8	0
576	Pharmacogenetics in Cardiovascular Medicine. <i>Current Genetic Medicine Reports</i> , 2016, 4, 119-129.	1.9	9
577	Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results. <i>Cardiovascular Therapeutics</i> , 2016, 34, 337-342.	1.1	11
578	Assessment of platelet function in patients receiving tirofiban early after primary coronary intervention. <i>Interventional Medicine & Applied Science</i> , 2016, 8, 135-140.	0.2	1
579	Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial. <i>Scientific Reports</i> , 2016, 6, 31838.	1.6	19
580	Effects of thermosensitive poly(N-isopropylacrylamide) on blood coagulation. <i>Journal of Materials Chemistry B</i> , 2016, 4, 3733-3749.	2.9	43
581	Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 245-253.	1.0	26
582	Prasugrel 5mg inhibits platelet P-selectin and GPIIb/IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 369-375.	1.0	4
583	CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention. <i>Thrombosis Research</i> , 2016, 147, 108-114.	0.8	10
584	Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2016, 47, 2791-2796.	1.0	15

#	ARTICLE	IF	CITATIONS
585	A joint allergist/cardiologist classification for thienopyridines hypersensitivity reactions based on their symptomatic patterns and its impact on the management strategies. <i>International Journal of Cardiology</i> , 2016, 222, 509-514.	0.8	3
586	Effect of long-term adherence to clopidogrel on the VASP-PRI after elective coronary stent implantation: a randomized controlled study. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1486-1497.	1.1	6
587	Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population. <i>Clinical and Translational Science</i> , 2016, 9, 23-28.	1.5	32
588	Relationship of paraoxonase-1 Q192R genotypes and in-stent restenosis and re-stenting in Chinese patients after coronary stenting. <i>Atherosclerosis</i> , 2016, 251, 305-310.	0.4	10
589	Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. <i>Platelets</i> , 2016, 27, 576-582.	1.1	28
590	New Developments in Platelet Cyclic Nucleotide Signalling: Therapeutic Implications. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 505-513.	1.3	8
591	Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease. <i>Circulation Journal</i> , 2016, 80, 791-801.	0.7	16
592	Anti-platelet Therapy Resistance – Concept, Mechanisms and Platelet Function Tests in Intensive Care Facilities. <i>The Journal of Critical Care Medicine</i> , 2016, 2, 6-15.	0.3	16
593	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	83
594	Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. <i>Thrombosis and Haemostasis</i> , 2016, 116, 638-650.	1.8	78
595	Association of VEGFR-2 Gene Polymorphisms With Clopidogrel Resistance in Patients With Coronary Heart Disease. <i>American Journal of Therapeutics</i> , 2016, 23, e1663-e1670.	0.5	9
596	Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor. <i>Cardiovascular Therapeutics</i> , 2016, 34, 209-215.	1.1	9
597	Dual antiplatelet therapy after coronary stenting. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1775-1787.	0.9	11
598	Expression of miRNA-26a in platelets is associated with clopidogrel resistance following coronary stenting. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 518-524.	0.8	18
599	Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2016, 25, 163-171.	0.7	29
600	Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 352-358.	1.1	20
601	Changes in CYP2C19 enzyme activity evaluated by the [¹³ C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity. <i>Journal of Breath Research</i> , 2016, 10, 017104.	1.5	17
602	Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 82, 64-78.	1.9	26

#	ARTICLE	IF	CITATIONS
603	Clopidogrel Response Variability. <i>Journal of Pharmacy Practice</i> , 2016, 29, 26-34.	0.5	24
604	Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2016, 15, 50.	2.7	25
605	A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. <i>European Heart Journal</i> , 2016, 37, 2722-2730.	1.0	52
606	Combination of P2Y12 reaction unit and percentage of platelet inhibition assessed by VerifyNow P2Y12 assay is a useful predictor of long-term clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , 2016, 139, 114-120.	0.8	11
607	Relationship Between Platelet Reactivity and Culprit Lesion Morphology. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 849-854.	2.3	13
608	A Safety Evaluation of Cangrelor in Patients Undergoing PCI. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 275-285.	1.0	12
609	Evaluation of the incremental prognostic value of the combination of CYP2C19 poor metabolizer status and ABCB1 3435 TT polymorphism over conventional risk factors for cardiovascular events after drug-eluting stent implantation in East Asians. <i>Genetics in Medicine</i> , 2016, 18, 833-841.	1.1	14
610	Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor. <i>Vascular Pharmacology</i> , 2016, 79, 11-15.	1.0	22
611	Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 321-334.	2.3	3
612	Platelet reactivity and hemorrhage risk in neurointerventional procedures under dual antiplatelet therapy. <i>Journal of NeuroInterventional Surgery</i> , 2016, 8, 949-953.	2.0	26
613	Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 663-670.	1.0	21
614	A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. <i>Pharmacogenomics Journal</i> , 2016, 16, 71-78.	0.9	35
615	Antithrombotic therapy for patients with STEMI undergoing primary PCI. <i>Nature Reviews Cardiology</i> , 2017, 14, 361-379.	6.1	76
616	Pharmacology: Inhibitors of P2Y12. , 2017, , 1253-1267.		1
617	Platelet reactivity in response to loading dose of atorvastatin or rosuvastatin in patients with stable coronary disease before percutaneous coronary intervention: The <sc>STATIPLAT</sc> randomized study. <i>Clinical Cardiology</i> , 2017, 40, 605-611.	0.7	9
618	Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. <i>Vascular Pharmacology</i> , 2017, 93-95, 42-47.	1.0	10
619	Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting. <i>Interventional Cardiology Clinics</i> , 2017, 6, 151-166.	0.2	4
620	Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponinâ€Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	30

#	ARTICLE	IF	CITATIONS
621	Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance. <i>Cardiology</i> , 2017, 137, 104-113.	0.6	10
622	Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity. <i>Journal of Zhejiang University: Science B</i> , 2017, 18, 37-47.	1.3	9
623	Efficacy of cilostazol-based dual antiplatelet treatment in patients undergoing carotid artery stenting. <i>Neurological Research</i> , 2017, 39, 695-701.	0.6	13
624	Association of measured platelet reactivity with changes in P2Y 12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the Treatment with ADP receptor inhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. <i>American Heart Journal</i> , 2017, 187, 19-28.	1.2	14
625	East Asian perspective on the interaction between proton pump inhibitors and clopidogrel. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1152-1159.	1.4	8
626	Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 355-361.	1.0	9
627	Facile alkylation of 4-nitrobenzotriazole and its platelet aggregation inhibitory activity. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5260-5267.	1.4	4
628	Optimization of Antiplatelet Therapy in STEMI. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 65.	0.4	2
630	A Novel Multiplex HRM Assay to Detect Clopidogrel Resistance. <i>Scientific Reports</i> , 2017, 7, 16021.	1.6	6
631	Feline Cardiogenic Arterial Thromboembolism. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2017, 47, 1065-1082.	0.5	23
632	P2Y12 receptor inhibitor resistance and coronary artery disease. <i>Current Opinion in Cardiology</i> , 2017, 32, 617-626.	0.8	1
633	Prasugrel versus clopidogrel in stent-assisted coil embolization of unruptured intracranial aneurysms. <i>Interventional Neuroradiology</i> , 2017, 23, 52-59.	0.7	38
634	The Prognostic Value of ADP-Induced Platelet Aggregation for Bleeding Complications in Low to Intermediate Risk Patients with Acute Coronary Syndrome Taking Clopidogrel After Percutaneous Coronary Intervention. <i>Heart Lung and Circulation</i> , 2017, 26, 49-57.	0.2	5
635	Impact of chronic kidney disease on platelet inhibition of clopidogrel and prasugrel in Japanese patients. <i>Journal of Cardiology</i> , 2017, 69, 752-755.	0.8	15
636	Acute stent thrombosis after stent-assisted coiling in an intracranial aneurysm patient carrying two reduced-function CYP2C19 alleles. <i>Medicine (United States)</i> , 2017, 96, e8920.	0.4	4
637	Antithrombotic therapy for acute coronary syndrome: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1240-1248.	1.8	41
638	Piperidine-Based Fused Biheterocycles. , 2017, , 269-286.		0
639	Induction of Diabetes Abolishes the Antithrombotic Effect of Clopidogrel in Apolipoprotein E-deficient Mice. <i>TH Open</i> , 2017, 01, e92-e100.	0.7	3

#	ARTICLE	IF	CITATIONS
640	The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics. <i>Cardiology Research and Practice</i> , 2017, 2017, 1-17.	0.5	44
641	Does i-T744C P2Y12 Polymorphism Modulate Clopidogrel Response among Moroccan Acute Coronary Syndromes Patients?. <i>Genetics Research International</i> , 2017, 2017, 1-7.	2.0	8
642	Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications. <i>Korean Journal of Anesthesiology</i> , 2017, 70, 13.	0.9	17
643	Correlations between High Platelet Reactivity, Extent of Coronary Artery Disease, and Periprocedural Myonecrosis in Patients with Acute Coronary Syndrome. <i>Chonnam Medical Journal</i> , 2017, 53, 147.	0.5	0
644	Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. <i>Pharmacogenomics Journal</i> , 2018, 18, 713-720.	0.9	19
645	Relation of Platelet Indexes to Platelet Reactivity and Periprocedural Myocardial Infarction in Patients Who Underwent Percutaneous Coronary Angioplasty. <i>American Journal of Cardiology</i> , 2018, 121, 1027-1031.	0.7	6
646	Asociación entre las escalas de riesgo isquémico y hemorrágico y el uso de los nuevos inhibidores del P2Y 12 en pacientes con síndrome coronario agudo. <i>Revista Española De Cardiología</i> , 2018, 71, 538-544.	0.6	5
647	Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatelet Atrial Fibrillation (GRAPE-AF) Registry. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 191-196.	1.3	6
648	Optimal pharmacological therapy in ST-elevation myocardial infarction—a review. <i>Netherlands Heart Journal</i> , 2018, 26, 296-310.	0.3	12
650	Impact of platelet reactivity on 5-year clinical outcomes following percutaneous coronary intervention: a landmark analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 496-503.	1.0	11
651	Relationship between adverse events and antiplatelet drug resistance in neurovascular intervention: a meta-analysis. <i>Journal of NeuroInterventional Surgery</i> , 2018, 10, 942-948.	2.0	19
652	Clinical implications of genetic variation in carboxylesterase drug metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 131-142.	1.5	21
653	Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 478-490.	1.6	61
654	Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. <i>Journal of Translational Medicine</i> , 2018, 16, 92.	1.8	41
655	Role of genetic testing in patients undergoing percutaneous coronary intervention. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 151-164.	1.3	57
656	The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts. <i>Expert Review of Hematology</i> , 2018, 11, 5-12.	1.0	17
657	Effects of PON1 Gene Promoter DNA Methylation and Genetic Variations on the Clinical Outcomes of Dual Antiplatelet Therapy for Patients Undergoing Percutaneous Coronary Intervention. <i>Clinical Pharmacokinetics</i> , 2018, 57, 817-829.	1.6	12
658	Platelet reactivity-adjusted antiplatelet therapy in patients with percutaneous coronary intervention: a meta-analysis of randomized controlled trials. <i>Platelets</i> , 2018, 29, 589-595.	1.1	3

#	ARTICLE	IF	CITATIONS
659	Effects of prasugrel on membrane potential and contractile activity of rat ventricular myocytes. <i>Pharmacological Reports</i> , 2018, 70, 156-160.	1.5	4
660	Cerium dioxide-doped carboxyl fullerene as novel nanoprobe and catalyst in electrochemical biosensor for amperometric detection of the CYP2C19*2 allele in human serum. <i>Biosensors and Bioelectronics</i> , 2018, 102, 94-100.	5.3	44
661	Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y 12 Inhibitors in Patients With Acute Coronary Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 538-544.	0.4	4
662	Diabetes and antiplatelet therapy: from bench to bedside. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 594-609.	0.7	45
663	Response to Letter of Li et al.: How to select antiplatelet therapy in patients with acute coronary syndrome, according to platelet function testing or pharmacogenomic testing?. <i>International Journal of Cardiology</i> , 2018, 271, 30.	0.8	0
664	Platelet Function Testing after Transcatheter Aortic Valve Implantation. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1681-1685.	1.8	8
665	Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 207-213.	0.7	9
666	Platelet Function Analyzer-200 P2Y Results Are Predictive of the Risk of Major Adverse Cardiac Events in Korean Patients Receiving Clopidogrel Therapy Following Acute Coronary Syndrome. <i>Annals of Laboratory Medicine</i> , 2018, 38, 413-419.	1.2	6
667	Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine. <i>Journal of Personalized Medicine</i> , 2018, 8, 8.	1.1	65
668	Ticagrelor Versus Clopidogrel as Part of Dual or Triple Antithrombotic Therapy: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 287-294.	1.3	31
669	Primary Percutaneous Coronary Intervention. , 2018, , 417-441.		0
670	Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel. <i>Drugs and Aging</i> , 2018, 35, 649-656.	1.3	12
671	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018, 15, 480-496.	6.1	180
672	Vasodilator-stimulated phosphoprotein-guided Clopidogrel maintenance therapy reduces cardiovascular events in atrial fibrillation patients requiring anticoagulation therapy and scheduled for percutaneous coronary intervention: a prospective cohort study. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 120.	0.7	7
673	Thromboelastography evaluation of low response to clopidogrel in patients with acute coronary syndrome. <i>International Journal of Gerontology</i> , 2018, 12, 43-47.	0.7	1
674	Association of Gene Polymorphisms in CYP2C19, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients undergoing percutaneous coronary intervention. <i>Journal of Indian College of Cardiology</i> , 2018, 8, 132-137.	0.1	0
675	CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han. <i>Gene</i> , 2018, 678, 226-232.	1.0	19
676	Omics Approaches Towards Transforming Personalized Medicine. , 2018, , 25-46.		0

#	ARTICLE	IF	CITATIONS
677	Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin. <i>Medicine (United States)</i> , 2018, 97, e11060.	0.4	3
678	High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis. <i>Journal of Cardiology</i> , 2019, 73, 51-57.	0.8	11
679	CYP2C19 Polymorphism is Associated With Amputation Rates in Patients Taking Clopidogrel After Endovascular Intervention for Critical Limb Ischaemia. <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 58, 373-382.	0.8	18
680	The effect of the CYP2C19*2 allele on cardiovascular outcomes in patients with coronary artery stenting: a prospective study. <i>Archives of Medical Science</i> , 2019, 15, 837-844.	0.4	4
681	Management of Antithrombotic Therapy in Atrial Fibrillation Patients UndergoingÂPCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 83-99.	1.2	126
682	Contemporary Antiplatelet Therapy and Clinical Outcomes of Japanese Patients With Acute Myocardial Infarctionâ€• Results From the Prospective Japan Acute Myocardial Infarction Registry (JAMIR) â€•. <i>Circulation Journal</i> , 2019, 83, 1633-1643.	0.7	17
683	The Effect of CYP2C19 and Nongenetic Factors on Clopidogrel Responsiveness in the MENA Region: A Systematic Review. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961987552.	0.7	3
684	Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. <i>PLoS ONE</i> , 2019, 14, e0210821.	1.1	5
685	Antithrombotic pharmacotherapy after transcatheter aortic valve implantation: an update. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 479-496.	0.6	9
686	Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile. <i>Annals of Neurology</i> , 2019, 86, 419-426.	2.8	21
687	Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e028595.	0.8	3
689	Genotype-guided personalization of antiplatelet treatment: A meta-analysis of patients with ACS or undergoing PCI. <i>Thrombosis Research</i> , 2019, 179, 87-94.	0.8	8
690	Predictive value of platelet reactivity unit (PRU) value for thrombotic and hemorrhagic events during flow diversion procedures: a meta-analysis. <i>Journal of NeuroInterventional Surgery</i> , 2019, 11, 1123-1128.	2.0	30
691	Optimal Antithrombotic Therapy for Patients with STEMI Undergoing PCI at High Risk of Bleeding. <i>Current Atherosclerosis Reports</i> , 2019, 21, 22.	2.0	3
692	Pharmacodynamic changes of platelet reactivity status in patients with chronic kidney disease after coronary artery stenting. <i>Biomedicine and Pharmacotherapy</i> , 2019, 113, 108773.	2.5	3
693	Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor. <i>Scientific Reports</i> , 2019, 9, 3924.	1.6	16
694	Antiplatelet Drugs in the Management of Coronary Artery Disease. , 2019, , 1017-1029.		0
695	Adenosine and the Cardiovascular System. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 449-464.	1.0	67

#	ARTICLE	IF	CITATIONS
696	High on-clopidogrel platelet reactivity and chronic kidney disease: a meta-analysis of literature studies. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 55-61.	0.4	9
697	Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. <i>European Heart Journal</i> , 2019, 40, 1553-1562.	1.0	62
698	Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial). <i>American Journal of Cardiology</i> , 2019, 123, 1494-1500.	0.7	19
699	Clinical outcomes and predictive model of platelet reactivity to clopidogrel after acute ischemic vascular events. <i>Chinese Medical Journal</i> , 2019, 132, 1053-1062.	0.9	12
700	Biomarkers for Antiplatelet Therapy. , 2019, , 139-148.		0
701	Rationale, Design, and Baseline Characteristics of the Prospective Japan Acute Myocardial Infarction Registry (JAMIR). <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 97-103.	1.3	18
702	Impact of immature platelet fraction on platelet reactivity during prasugrel maintenance treatment. <i>Platelets</i> , 2019, 30, 915-922.	1.1	3
703	Tailoring Antiplatelet Therapy in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 33-37.	1.1	11
704	Effectiveness and Safety of Clopidogrel Co-administered With Statins and Proton Pump Inhibitors: A Korean National Health Insurance Database Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 182-194.	2.3	4
705	Platelet Functions are Decreased in Obesity and Restored after Weight Loss: Evidence for a Role of the SERCA3-Dependent ADP Secretion Pathway. <i>Thrombosis and Haemostasis</i> , 2019, 119, 384-396.	1.8	13
706	Efficacy and safety of prasugrel therapy for intracranial aneurysms with endovascular treatment: A meta-analysis. <i>Journal of the Neurological Sciences</i> , 2019, 397, 174-178.	0.3	9
707	Antiplatelet effects of aspirin and clopidogrel after left atrial appendage (LAA) occluder implantation. <i>International Journal of Cardiology</i> , 2019, 275, 95-100.	0.8	5
708	Long-term and short-term duration of thienopyridine therapy after coronary stenting in patients with chronic kidney disease a meta-analysis of literature studies. <i>Platelets</i> , 2020, 31, 483-489.	1.1	3
709	Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 793-801.	0.7	6
710	Comparison of the hypoglycemic and antithrombotic (anticoagulant) actions of whole bovine and camel milk in streptozotocin-induced diabetes mellitus in rats. <i>Journal of Dairy Science</i> , 2020, 103, 30-41.	1.4	22
711	Antiplatelet Therapy in Flow Diversion. <i>Neurosurgery</i> , 2020, 86, S47-S52.	0.6	40
712	High glycated albumin is an independent predictor of low response to clopidogrel in ACS patients: a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2020, 19, 171.	2.7	14
713	Serum uric acid level negatively correlated with the prevalence of clopidogrel low response in patients undergoing antiplatelet treatment with aspirin and clopidogrel. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 2215-2220.	1.1	2

#	ARTICLE	IF	CITATIONS
714	Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta-analysis. <i>Scientific Reports</i> , 2020, 10, 16794.	1.6	14
715	Association between CYP2C9 polymorphisms and ischemic stroke following endovascular neurointervention. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104901.	0.7	3
716	Platelet Inhibition with Ticagrelor versus Clopidogrel in Diabetic Patients after Percutaneous Coronary Intervention for Chronic Coronary Syndromes. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1221-1229.	1.8	8
717	Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. <i>American Heart Journal</i> , 2020, 228, 1-7.	1.2	7
718	Effectiveness and safety of high dose clopidogrel plus aspirin in ischemic stroke patients with the single CYP2C19 loss-of-function allele: a randomized trial. <i>BMC Neurology</i> , 2020, 20, 395.	0.8	2
719	De-Escalation of Antiplatelet Treatment in Patients with Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Review of the Current Literature. <i>Journal of Clinical Medicine</i> , 2020, 9, 2983.	1.0	9
720	Clopidogrel drug interactions: a review of the evidence and clinical implications. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 1079-1096.	1.5	8
721	Search for a practical approach for detection of clopidogrel resistance: Comparison of light transmission aggregometry and INNOVANCE [®] PFA P2Y cartridge and correlation with CYP2C19 variants. <i>International Journal of Laboratory Hematology</i> , 2020, 42, e189-e191.	0.7	2
722	Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes. <i>JACC Basic To Translational Science</i> , 2020, 5, 419-428.	1.9	18
723	Interethnic differences in the prevalence of main cardiovascular pharmacogenetic biomarkers. <i>Pharmacogenomics</i> , 2020, 21, 677-694.	0.6	6
724	Platelet activity with hemoglobin level in patients with hemodialysis. <i>Medicine (United States)</i> , 2020, 99, e19336.	0.4	1
725	Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. <i>Journal of the American College of Cardiology</i> , 2020, 75, 578-586.	1.2	66
726	Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 606-617.	1.1	90
727	Genotype-guided treatment of oral P2Y12 inhibitors: where do we stand?. <i>Pharmacogenomics</i> , 2020, 21, 83-86.	0.6	5
728	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	6.1	87
729	Genetic polymorphisms of high platelet reactivity in Chinese patients with coronary heart disease under clopidogrel therapy. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 158-166.	1.0	4
730	Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management. <i>Nature Reviews Cardiology</i> , 2021, 18, 37-57.	6.1	42
731	Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. <i>Platelets</i> , 2021, 32, 591-600.	1.1	22

#	ARTICLE	IF	CITATIONS
732	Safety and efficacy of P2Y ₁₂ inhibitor monotherapy in patients undergoing percutaneous coronary interventions. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 9-21.	1.0	18
733	Associations of PER3 polymorphisms with clopidogrel resistance among Chinese Han people treated with clopidogrel. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23713.	0.9	4
734	Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 741-747.	1.0	10
735	Viscoelastic Haemostatic Assays in Cardiovascular Critical Care. <i>Cardiac Failure Review</i> , 2020, 7, e01.	1.2	5
736	The expression profile of platelet-derived miRNA in coronary artery disease patients with clopidogrel resistance. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00751.	1.1	4
737	Antithrombotic strategies in elderly patients with acute coronary syndrome. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 232-245.	0.7	2
738	Precision Treatment in ACS—Role of Assessing Fibrinolysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 929.	1.0	2
739	Membrane Environment Modulates Ligand-Binding Propensity of P2Y ₁₂ Receptor. <i>Pharmaceutics</i> , 2021, 13, 524.	2.0	4
740	Small bowel ulcer bleeding due to suspected clopidogrel use in a patient with clopidogrel resistance: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 3689-3695.	0.3	1
741	CYP2C19 genotype-directed P2Y ₁₂ inhibitor antiplatelet therapy normalizes risk for major adverse cardiovascular events after percutaneous coronary intervention. <i>Indian Heart Journal</i> , 2021, 73, 281-288.	0.2	1
742	Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 670155.	1.6	27
743	Mechanistic insights into the CYP2C19 genetic variants prevalent in the Indian population. <i>Gene</i> , 2021, 784, 145592.	1.0	2
744	Selatogrel: A Novel Subcutaneous P2Y ₁₂ Inhibitor. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 79, 161-167.	0.8	6
745	MiR-223 or miR-126 predicts resistance to dual antiplatelet therapy in patients with ST-elevation myocardial infarction. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110162.	0.4	5
746	Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives. <i>Journal of the American Heart Association</i> , 2021, 10, e022125.	1.6	31
747	An update on antithrombotic therapy in atrial fibrillation patients in long-term ambulatory setting after percutaneous coronary intervention: where do we go from here?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2033-2051.	0.9	3
748	Prevalence of CYP2C19*2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup. <i>Drug Metabolism and Personalized Therapy</i> , 2021, .	0.3	1
749	Impact of Comorbidities and Antiplatelet Regimen on Platelet Reactivity Levels in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, 463-473.	0.8	1

#	ARTICLE	IF	CITATIONS
750	Platelet physiology and pharmacology—relevant considerations for patient care. , 2021, , 15-45.		0
752	Association of PON1, P2Y12 and COX1 with Recurrent Ischemic Events in Patients with Extracranial or Intracranial Stenting. PLoS ONE, 2016, 11, e0148891.	1.1	29
753	Bleeding Outcomes Associated with Coronary Artery Bypass Graft Surgery and Recent Clopidogrel Exposure. Heart Surgery Forum, 2015, 16, 70.	0.2	4
754	Elevated Serum Levels of Alkaline Phosphatase and the Risk of Low Responsiveness to Clopidogrel. International Heart Journal, 2020, 61, 1135-1141.	0.5	1
755	Current Concepts in the Clinical Utility of Platelet Reactivity Testing. Interventional Cardiology Review, 2013, 8, 100.	0.7	4
756	Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia. Journal of King Abdulaziz University, Islamic Economics, 2017, 22, 31-37.	0.5	12
757	Clopidogrel. American Journal of Cardiovascular Drugs, 2012, 12, 361-374.	1.0	7
758	Novel Strategies in Anti-Platelet Treatment for Coronary Artery Disease. Vascular Disease Prevention, 2009, 6, 75-84.	0.2	5
759	Comparing Allergist and Cardiologist Considerations for the Optimal Management of Thienopyridines Hypersensitivity. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2019, 19, 2-12.	0.6	1
760	Risk factors for venous and arterial thrombosis. Blood Transfusion, 2011, 9, 120-38.	0.3	294
761	Relationship between cytochrome P450 2C19*17 genotype distribution platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel. Zhong Xi Yi Jie He Xue Bao, 2012, 10, 647-654.	0.7	9
763	Relationship between clopidogrel-related polymorphisms and variable platelet reactivity at 1 year: A cohort study from Han Chinese. Journal of Research in Medical Sciences, 2016, 21, 111.	0.4	7
764	Aspirin and clopidogrel resistance in Indian patients with ischemic stroke and its associations with gene polymorphisms: A pilot study. Annals of Indian Academy of Neurology, 2019, 22, 147.	0.2	15
765	Impact of cytochrome P450 2C19*2 polymorphism on the clinical cardiovascular events after stent implantation in patients receiving clopidogrel of a southern Tunisian region. World Journal of Cardiovascular Diseases, 2013, 03, 4-10.	0.0	7
766	Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome.. EuroIntervention, 2009, 5, 325-329.	1.4	123
767	Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial. EuroIntervention, 2014, 10, 204-211.	1.4	18
768	Dual antiplatelet therapy after percutaneous coronary intervention: entering the final chapter?. EuroIntervention, 2019, 15, e475-e478.	1.4	5
769	Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update. EuroIntervention, 2010, 6, 39-45.	1.4	5

#	ARTICLE	IF	CITATIONS
770	The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. <i>EuroIntervention</i> , 2013, 9, 316-327.	1.4	36
771	Endovascular treatment of extracranial vertebral artery stenosis. <i>World Journal of Radiology</i> , 2012, 4, 391.	0.5	31
772	Ticagrelor Use in Indian Patients Undergoing Neuroendovascular Procedures: A Single Center Experience. <i>Neurointervention</i> , 2019, 14, 125-130.	0.5	10
773	Detection of Clopidogrel Resistance Using ADP Induced Aggregometry with Specific Inhibitor PGE1. <i>Clinical Laboratory</i> , 2014, 60, 1475-80.	0.2	3
774	Outcomes after ticagrelor versus clopidogrel treatment in end-stage renal disease patients with acute myocardial infarction: a nationwide cohort study. <i>Scientific Reports</i> , 2021, 11, 20826.	1.6	4
775	Gene polymorphisms of insulin secretion signaling pathway associated with clopidogrel resistance in Han Chinese population. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23970.	0.9	4
776	Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial. <i>Stroke</i> , 2022, 53, 465-472.	1.0	10
777	Stent thrombosis in the era of drug-eluting stents. , 2008, , 211-219.		3
779	Current status and limitation of thienopyridine antiplatelets. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2009, 20, 329-335.	0.1	0
780	Early Treatment of ST-segment-elevation Myocardial Infarction Incorporating Results of the FINESSE Trial. <i>European Cardiology Review</i> , 2009, 5, 85.	0.7	1
781	Failure of therapy or resistance to antiplatelet drugs?. <i>Cor Et Vasa</i> , 2009, 51, 41-44.	0.1	0
782	Determinants of thrombin generation, fibrinolytic activity and endothelial dysfunction in dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2009, 20, 48-55.	0.1	0
783	Prasugrel: A New Antiplatelet for the Management of Acute Coronary Syndrome. <i>Hospital Pharmacy</i> , 2010, 45, 26-30.	0.4	0
784	Manejo de los antiagregantes en el perioperatorio. , 2010, , 123-140.		0
785	Special Management of Diabetic Patients with STEMI. , 2010, , 183-196.		0
786	Association between CYP2C19*2 variant and clinical outcome in Clopidogrel treated patients from Republic of Macedonia. <i>Makedonsko Farmaceutski Bilten</i> , 2011, 56, 37-44.	0.0	0
787	Nonresponsiveness to Antiplatelet Therapy. , 2011, , 222-231.		0
788	Molecular genetics of atherosclerosis and acute coronary syndromes. , 2011, , 35-43.		0

#	ARTICLE	IF	CITATIONS
789	Characterization and Evaluation of Clopidogrel Response Testing in a Community Hospital Setting. Journal of Clinical & Experimental Cardiology, 2011, 02, .	0.0	0
791	THIENOPYRIDINES: PLATELET ADP RECEPTOR ANTAGONIST. Journal of Drug Delivery and Therapeutics, 2011, 1, .	0.2	0
794	The effectiveness of clopidogrel in the prevention of thrombotic complications in patients with acute coronary syndrome and genetic factors. Kazan Medical Journal, 2012, 93, 294-297.	0.1	1
795	Treatment algorithm in patients with STEMI. , 2012, , 347-358.		0
797	Management of a patient on dual antiplatelet therapy presented for living donor liver transplant. Case Reports in Clinical Medicine, 2013, 02, 115-118.	0.1	0
798	Importance of pharmacogenetics for therapeutic use of clopidogrel. Racionalna Terapija, 2013, 5, 75-83.	0.1	0
799	Pharmacogenomics and Personalized Medicine of the Antiplatelet Drugs. , 2013, , 469-506.		0
801	Suboptimal platelet response to clopidogrel after percutaneous coronary intervention in patients with acute coronary syndrome is not associated with total platelet count and mean platelet volume. Cardiologia Croatica, 2013, 8, 279-279.	0.0	0
802	Implications of the VerifyNow P2Y12 Assay on Patient Outcomes. Open Journal of Thoracic Surgery, 2014, 04, 78-85.	0.1	1
803	Genetic Determinants of CYP2C19 Gene *2 and *3 Loss of Function Alleles and Response to Anti Platelet Therapy (Clopidogrel) and Cardiovascular Events. (A Study in Kashmir, North India). Biology and Medicine (Aligarh), 2015, 07, .	0.3	2
804	Right Ventricular Dysfunction in Myocardial Infarction: A New Risk Factor for Clopidogrel Resistance?. Journal of Clinical & Experimental Cardiology, 2015, 06, .	0.0	0
805	Clopidogrel-statin interaction: A missing links. Hospital Pharmacology, 2016, 3, 395-401.	0.1	2
806	Analysis of a complex physiology-directed model for inhibition of platelet aggregation by clopidogrel. Discrete and Continuous Dynamical Systems, 2017, 37, 945-961.	0.5	0
807	Possibility of active management of the target P2Y12 reaction unit range in patients undergoing aneurysmal neurointerventional procedures. No Junkan Taisha = Cerebral Blood Flow and Metabolism, 2017, 28, 241-247.	0.1	1
808	Effects of Platelet Number and Platelet Indices on Platelet Reactivity in Patients Treated with Clopidogrel or Ticagrelor. Korean Journal of Medicine, 2017, 92, 526-532.	0.1	0
809	Dual antiplatelet therapy in coronary artery disease. Srce I Krvni Sudovi, 2018, 37, 45-50.	0.1	0
810	Comparison of antiplatelet treatment in patients with clopidogrel nonresponders with or without carriage of <i>CYP2C19</i> polymorphism. Korean Journal of Internal Medicine, 2018, , .	0.7	1
811	On-treatment platelet reactivity in the era of new ADP receptor blockers: data from a real-world clinical practice. Acta Medica Martiniana, 2018, 18, 34-39.	0.4	1

#	ARTICLE	IF	CITATIONS
812	A focused review on optimal coronary revascularisation in patients with chronic kidney disease. <i>AsiaIntervention</i> , 2019, 5, 32-40.	0.1	3
813	Antiplatelet Therapy Considerations in Women. <i>Cardiovascular Innovations and Applications</i> , 2019, 3, .	0.1	0
814	Current management approaches to patients with atrial fibrillation and percutaneous coronary intervention. <i>Medical Alphabet</i> , 2019, 2, 12-17.	0.0	0
815	Optimal Antithrombotic Therapy in Patients with Atrial Fibrillation During Percutaneous Coronary Intervention. <i>Doctor Ru</i> , 2020, 19, 6-13.	0.1	1
817	Isparta ve ÅSevresinde klopidoğrel direncinin araÅYtÅ±rÅ±lmasÅ±. SÅ¼leyman Demirel Åœniversitesi TÅ±p FakÅ¼ltesi Dergisi, 0, , .	0.0	0
818	An Observational Study of the Relationship Between Outcome and Platelet Reactivity in Chinese Patients Undergoing PCI Loading with 600 mg Clopidogrel. <i>Cardiovascular Innovations and Applications</i> , 2020, 5, .	0.1	0
819	Influence of <i>GAS5</i> /MicroRNA-223/P2Y12 Axis on Clopidogrel Response in Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2021, 10, e021129.	1.6	9
820	ASSOCIATION BETWEEN SMOKING AND THE ANTIPLATELET EFFECT OF CLOPIDOGREL. <i>Juvenis Scientia</i> , 2020, 6, 14-24.	0.1	0
821	Allele and Genotype Frequencies of CYP2C19 in Patients with Drug-Eluting Stents Following Percutaneous Coronary Intervention in Southwest of Iran. <i>Jundishapur Journal of Chronic Disease Care</i> , 2020, 9, .	0.1	0
822	Impact of Pancreatic Î²-Cell Function on Clopidogrel Responsiveness and Outcomes in Chinese Nondiabetic Patients Undergoing Elective Percutaneous Coronary Intervention. <i>Cardiovascular Drugs and Therapy</i> , 2021, , 1.	1.3	2
824	Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part) Tj ETQq0 0.0 rgBT /Overlock 10	0.1	12
825	Antithrombotic therapy in patients with acute coronary syndromes: a balance between protection from ischemic events and risk of bleeding. <i>American Journal of Cardiovascular Disease</i> , 2011, 1, 255-63.	0.5	1
826	Early dual antiplatelet therapy in stroke: should we take the CHANCE?. <i>Annals of Translational Medicine</i> , 2015, 3, 177.	0.7	2
827	Non-Carriers of Reduced-Function CYP2C19 Alleles are Most Susceptible to Impairment of the Anti-Platelet Effect of Clopidogrel by Proton-Pump Inhibitors: A Pilot Study. <i>Acta Cardiologica Sinica</i> , 2016, 32, 215-22.	0.1	4
828	Development of a new HPLC method for simultaneous determination of clopidogrel and its major metabolite using a chemometric approach. <i>Current Health Sciences Journal</i> , 2015, 41, 11-21.	0.2	4
829	Simultaneous Analysis of Clopidogrel Bisulfate, Acetylsalicylic Acid and Atorvastatin calcium in Tablets by HPLC Method. <i>Current Health Sciences Journal</i> , 2015, 41, 172-178.	0.2	1
830	The Importance of Platelets Response during Antiplatelet Treatment after Ischemic Strokeâ€”Between Benefit and Risk: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1043.	1.8	11
831	Antiplatelet and myocardial protective effect of Shexiang Tongxin Dropping Pill in patients undergoing percutaneous coronary intervention: A randomized controlled trial. <i>Journal of Integrative Medicine</i> , 2022, 20, 126-134.	1.4	6

#	ARTICLE	IF	CITATIONS
832	ABCDâ€œGENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILORâ€œPCI Trial. <i>Journal of the American Heart Association</i> , 2022, 11, e024156.	1.6	22
833	Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention. <i>Trends in Cardiovascular Medicine</i> , 2023, 33, 133-138.	2.3	21
834	Increased frequency of <i>CYP2C19</i> lossâ€œofâ€œfunction alleles in clopidogrelâ€œtreated patients with recurrent cerebral ischemia. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3335-3340.	1.1	3
835	A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases. <i>Medical Science Monitor</i> , 2022, 28, e935664.	0.5	3
836	High triglyceride is an independent predictor of high on-treatment platelet reactivity in ischemic stroke patients. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106448.	0.7	1
837	Prevalence of <i>CYP2C19*2</i> carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup. <i>Drug Metabolism and Personalized Therapy</i> , 2022, 37, 35-40.	0.3	2
838	Antithrombotic Therapy Following Transcatheter Aortic Valve Replacement. <i>Journal of Clinical Medicine</i> , 2022, 11, 2190.	1.0	3
839	Impact of the ABCDâ€œGENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multiâ€œSite, Realâ€œWorld Investigation. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 146-155.	2.3	7
840	Circadian variations of platelet reactivity on clopidogrel in patients treated with elective percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, , 1.	1.0	0
841	Efficacy and Safety of De-escalation of Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Clinical Trials. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 80, 226-235.	0.8	1
844	Association of Î±2A-Adrenergic Receptor Genetic Variants with Platelet Reactivity in Chinese Patients on Dual Antiplatelet Therapy Undergoing Percutaneous Coronary Intervention. <i>Biomedical and Environmental Sciences</i> , 2017, 30, 898-906.	0.2	1
847	De-escalation strategies of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention for acute coronary syndrome. <i>Cardiovascular Prevention and Pharmacotherapy</i> , 2022, 4, 63-69.	0.0	0
849	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 829-844.	6.1	30
850	Grand challenges in stroke genomics. , 0, 1, .		1
851	Clinical pharmacology of antiplatelet drugs. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 1177-1197.	1.3	14
852	Clinical Impact of Platelet Reactivity and Gene Polymorphisms in Patients With Ischemic Heart Disease After Percutaneous Coronary Intervention. , 2022, 1, 168.		0
853	Discordance in tests used to detect inhibition of the P2Y12 receptor in patients undergoing interventional neuroradiology procedures. <i>Interventional Neuroradiology</i> , 0, , 159101992211228.	0.7	0
854	Genetic polymorphism of clopidogrel metabolism related gene <i>CYP2C19</i> gene in Chinese from Foshan area of Guangdong Province. <i>Hematology</i> , 2022, 27, 1056-1061.	0.7	1

#	ARTICLE	IF	CITATIONS
855	The developmental journey of therapies targeting purine receptors: from basic science to clinical trials. <i>Purinergic Signalling</i> , 2022, 18, 435-450.	1.1	3
856	Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 5605.	1.0	1
857	P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 340.	0.8	1
858	Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of Prasugrel in Healthy Male Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 0, , .	0.8	1
859	Bioactive food components and their inhibitory actions in multiple platelet pathways. <i>Journal of Food Biochemistry</i> , 2022, 46, .	1.2	5
860	Integrating pharmacogenomics into clinical trials of hearing disorders. <i>Journal of the Acoustical Society of America</i> , 2022, 152, 2828-2839.	0.5	2
861	Anticoagulation and Antiplatelet Agents in Peripheral Arterial Interventions. <i>Seminars in Interventional Radiology</i> , 2022, 39, 364-372.	0.3	0
862	New Approaches in P2Y12 Receptor Blocker Drugs Use. <i>Frontiers in Cardiovascular Drug Discovery</i> , 2022, , 141-190.	0.0	0
863	A Systematic Review of Clopidogrel Resistance in Vascular Surgery: Current Perspectives and Future Directions. <i>Annals of Vascular Surgery</i> , 2023, 91, 257-265.	0.4	4
864	Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet responsiveness in patients with ST-segment elevation myocardial infarction: the ECCLIPSE-STEMI trial. <i>Journal of Thrombosis and Thrombolysis</i> , 0, , .	1.0	1
865	Switching Between Intravenous and Oral P2Y12 Inhibition. <i>JACC: Cardiovascular Interventions</i> , 2023, 16, 47-49.	1.1	0
866	Clinical outcomes of individualized antiplatelet therapy based on platelet function test in patients after percutaneous coronary intervention: a systematic review and meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2022, Publish Ahead of Print, .	0.8	1
867	Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease. <i>Vascular Pharmacology</i> , 2023, 148, 107143.	1.0	3
868	Monitoring antiplatelet therapy: where are we now?. <i>Journal of Cardiovascular Medicine</i> , 2023, 24, e24-e35.	0.6	4
869	Cytochrome P450 2C19 Polymorphisms and Its Association With Major Adverse Cardiac Events in Post-coronary Intervention Patients on Clopidogrel in the Tertiary Care Center. <i>Cureus</i> , 2023, , .	0.2	0
870	CD80 DNA methylation and single-nucleotide polymorphism associated with clopidogrel response: a whole-genome DNA methylation analysis in acute coronary syndrome. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 100093.	1.0	0
871	Decreased platelet miR-199a-5p level might lead to high on-clopidogrel platelet reactivity in patients with coronary artery disease. <i>Platelets</i> , 2023, 34, .	1.1	0